

(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property Organization
International Bureau



(43) International Publication Date
11 July 2002 (11.07.2002)

PCT

(10) International Publication Number
WO 02/053138 A2

(51) International Patent Classification⁷: **A61K 31/00**

(21) International Application Number: **PCT/IE02/00001**

(22) International Filing Date: **2 January 2002 (02.01.2002)**

(25) Filing Language: **English**

(26) Publication Language: **English**

(30) Priority Data:
S2001/0002 2 January 2001 (02.01.2001) IE

(71) Applicant and

(72) Inventor: **SHANAHAN-PRENDERGAST, Elisabeth**
[IE/IE]; Baybush, Straffen, County Kildare (IE).

(74) Agent: **MACLACHLAN & DONALDSON; 47 Merrion**
Square, Dublin 2 (IE).

(81) Designated States (national): **AE, AG, AL, AM, AT, AU,**
AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU,

CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH,
GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC,
LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW,
MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SD, SE, SG,
SI, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ,
VN, YU, ZA, ZM, ZW.

(84) Designated States (regional): **ARIPO patent (GH, GM,**
KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW),
Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM),
European patent (AT, BE, CH, CY, DE, DK, ES, FI, FR,
GB, GR, IE, IT, LU, MC, NL, PT, SE, TR), OAPI patent
(BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR,
NE, SN, TD, TG).

Published:

— *without international search report and to be republished
upon receipt of that report*

For two-letter codes and other abbreviations, refer to the "Guidance Notes on Codes and Abbreviations" appearing at the beginning of each regular issue of the PCT Gazette.



WO 02/053138 A2

(54) Title: **TREATMENT FOR INHIBITING NEOPLASTIC LESIONS**

(57) Abstract: The invention discloses the use of incensole and/or furanogermacrene, derivatives metabolites and precursors thereof in the treatment of neoplasia, particularly resistant neoplasia and immunodysregulatory disorders. These compounds can be administered alone or in combination with conventional chemotherapeutic, anti-rival, anti-parasite agents, radiation and/or surgery.

- 1 -

"Treatment for inhibiting neoplastic lesions"

5 The present invention relates to a method for the selective inhibition of neoplastic cells, for example for the treatment, inhibition or prevention of precancerous lesions, tumours, cancer growth or other neoplasias in mammals. This invention also relates to the use of the compounds of the present invention including incensole and/or furanogermacren, derivatives, metabolites, analogues, mimic molecules and to compositions containing the compounds of the present invention
10 including incensole and/or furanogermacren, derivatives, metabolites, analogues, mimic molecules.

Cancer develops from changes in the DNA, or genetic material, of the body's cells, causing them to develop into precancerous lesions. Such lesions exhibit a strong tendency to develop into malignant tumours, or cancer. Such lesions include
15 lesions of the breast (that can develop into breast cancer), lesions of the skin (that can develop into malignant melanoma or basal cell carcinoma), colonic adenomatous polyps (that can develop into colon cancer), and other such neoplasms.

Cancer may take years to develop. The process typically begins with some
20 disruption to the DNA of a cell, the genetic code that directs the life of the cell. Many things, such as diet, tobacco, sun exposure or certain chemicals can cause such disruptions. Some cells will enter a precancerous phase, known as dysplasia. Some cells will also enter the state of *carcinoma in situ*, in which the cancer cells are restricted to a microscopic site and do not pose a great threat. Eventually,
25 unless the body's own immune system takes care of the wayward cells either on its own or by being enhanced by specific chemicals, a tumour will develop. It may take as long as 30 years for a tumour to go through the entire process and become large enough to produce clinical symptoms.

Anyone can get cancer, including children, but it is most common in people over
30 the age of 50. This year about 1.22 million people in the United States will be diagnosed with cancer (not including the more than 1 million annual cases of basal

- 2 -

and squamous-cell skin cancers.) About 563,000 people will die of cancer this year.

Treatment for cancer has progressed rapidly over the last 30 years. Doctors generally prescribe three main treatments for cancer: surgery, radiation therapy, chemotherapy or a combination of these. Choosing a course of medical treatment
5 depends largely on the cancer type, stage of progression, and location.

Surgery is generally advisable when physicians can safely remove the cancer from the body. In situations where the cancerous cells have spread, surgeons sometimes must remove large areas of healthy tissue along with the tumour to insure that no malignancy remains. In these cases, physicians remove lymph
10 nodes from the tumour area because cancer can spread through nodes. However, unfortunately most cancers are discovered too late for surgical cure. In many cases, the patient does not experience symptoms until the cancer has progressed to a malignant stage.

Radiation therapy is used to destroy cancer cells. Ironically, radiation can *cause* and *destroy* cancer. Side effects of radiation therapy include radiation sickness,
15 which are nausea and skin redness in the tumour area.

Chemotherapy uses poison drugs that take advantage of cancer cells' rapid growth and consumption of large amounts of nutrients. Chemotherapy side effects include nausea and temporary full or partial hair loss. Antimetabolites, one group of these
20 drugs, work by mimicking the nutrients the body's cells consume. Physicians inject these drugs into the bloodstream, where they travel throughout the body, consumed by every cell. Rapidly growing cancerous cells consume much more of the poisonous drugs than do normal cells. As a result, the drugs destroy cancerous cells faster than normal cells. Cells reproduce by duplicating their genetic code, or
25 DNA. Another group of chemotherapy drugs interferes with the duplication of DNA, so cells cannot reproduce. Chemotherapy drugs act on all the patient's cells -- the cancerous cells and the healthy cells. A physician's challenge is to administer the drugs to kill only the cancer cells, not the healthy cells. Side effects such as those immediately described prevent the long term or recurrent use of these drugs.
30 Furthermore, there are an increasing number of effective drugs that can no longer be used due to resistance by the causative agent.

- 3 -

Researchers have refined these three cancer treatments (surgery, radiation therapy and chemotherapy) over the past 20 years. As a result, the survival rate among cancer patients has increased dramatically. But, the success of any treatment for cancer depends on how much the cancer has spread before
5 treatment begins. Once cancer metastasises, or spreads into different areas of the body, treating it with surgery, radiation therapy or chemotherapy becomes more difficult. As the tumour mass increases and cancerous cells proliferate, the cancer may become resistant to any type of therapy medicine can provide.

Early cancer detection is critical to successful treatment. If physicians destroy
10 tumours before they have had an opportunity to spread, a person with cancer has a much greater chance for survival.

The search for drugs useful for treating and preventing cancer is intensive. Indeed, much of the focus of cancer research today is on the prevention of cancer because chemotherapy for cancer itself is often not effective and has severe side effects.
15 Cancer chemoprevention is important for recovered cancer patients whom retain a risk of cancer recurrence. Also, cancer chemoprevention is important for individuals who, have not yet had cancer, but have hereditary factors that place them at risk of developing cancer. With the development of new genetic screening technologies, it is easier to identify patients with high-risk genetic factors, whom
20 would greatly benefit from chemopreventative drugs. Therefore finding such anti-cancer drugs that can be used for prolonged preventive use is of vital interest.

Unfortunately, most chemotherapeutic drugs have serious side effects that prohibit their long-term use, or use in otherwise healthy individuals with precancerous lesions. There side effects, which are a result of non-specific toxicity of the drugs,
25 immunosuppression and other toxicities. For this reason there is a need to identify new drug candidates for therapy of patients with precancerous lesions that do not have such serious side effects in humans.

The in vitro anti-tumour activity of several natural products has recently been examined to identify new compounds that inhibit the cancer cells whilst having
30 lower side effects, as described in US580925; USUS6051565; US6080741; US5578637; US5578637; US5663196; US5602184; US5817816; and US56077840

- 4 -

to list but a few. A new group of drugs, utilizing monoclonal antibodies, designed to affect only cancer cells, leaving healthy cells intact have been tested. US 5064823 discloses the anticancer activity of pentacyclic triterpenoid compounds which possess topoisomerase inhibitory activity. US 5876728 is directed to a composition for treating cancer that contains at least three herbal extracts. These previously described compounds are unrelated to the present invention.

However, despite these developments, there exists a continuing need for chemotherapeutic agents which inhibit tumour growth, especially solid tumour growth and which have an adequate therapeutic index to be effective for in vivo treatment.

The correlation between the compounds of the present invention, incensole and furanogermacren, derivatives, metabolites, analogues and/or mimic molecules and neoplasia was not recognised prior to the work of the applicant. Accordingly the following provides information on each of these topics.

The present invention is directed to a composition comprising one or more compound of the present invention described herein, their derivatives, metabolites, analogues and/or mimic molecules with pharmaceutical acceptable additives, diluents, carriers, excipients and pharmaceutical salts thereof.

The present invention is further directed to a pharmaceutical formulation comprising a composition as described herein and a pharmaceutically acceptable carrier thereof.

The present invention is further directed to the use of the pharmaceutical formulation for the manufacture of a medicament for treatment of a mammal suffering from a neoplasia comprising a pharmaceutical formulation as described herein.

The present invention is also directed to the use of the pharmaceutical formulation for the manufacture of a medicament for sensitising a resistant neoplasia to subsequent therapy comprising administering to a patient in need thereof a therapeutically effective amount of composition as previously described.


- 5 -

The present invention is also directed to the use of a pharmaceutical formulation for the manufacture of a medicament for treatment of a mammal suffering from an immunodysregulatory condition comprising a composition as described herein to a
 5 subject.


DETAILED DESCRIPTION OF THE INVENTION

The present invention is directed to a composition comprising one or more
 10 compound of the present invention described herein, their derivatives, metabolites, analogues and/or mimic molecules with pharmaceutical acceptable additives, diluents, carriers, excipients and pharmaceutical salts thereof.

In one embodiment, the compounds of the present invention are selected from the
 15 group comprising:



Formula (1)



Formula (2)

wherein for Formula (1)

Bonds between carbons 9-10, 10-1, 1-2, 2-3, 3-4, 4-5, 5-6, can be either single or
 20 double with the proviso that any two or more double bonds are separated by a single bond.

Compounds also include those containing epoxide rings formed between carbons
 9-10, 10-1, 1-2, 2-3, 3-4, 4-5 with the proviso that any two or more epoxide rings are
 25 separated by a single bond.

- 6 -

wherein for Formula (2)

the carbocyclic ring can have optionally up to 7 endocyclic/exocyclic double bonds with the proviso that any two or more double bonds are separated by single bonds;

5

Carbon atoms for Formula (1) or (2) can be singly or multiply substituted, optionally and independently by:

an oxo substituent, H, alkyl, aryl, a heterocyclic radical, halogen, alkoxycarbonyl (C1-C5) or carboxyl, hydroxyl, alkoxy (C1-C5), amido, alkyl amido (C1-C5), amino, 10 mono and dialkyl amino (C1-C5), alkyl carbamoyl (C1-C5), thiol, alkylthio (C1-C5);

in addition substituents may form a spiro ring around the carbon atom to which they are attached or they can form fused or bridged rings to adjacent carbon atoms 15 which may be saturated or unsaturated;

Substituents on the aryl or heterocyclic radical are selected from the group consisting essentially of: halogen, alkyl (C1-C5), hydroxyl, alkoxy (C1-C5), alkoxycarbonyl, (C1-C5), carboxyl, amido, alkyl amido (C1-C5), amino, mono and 20 dialkyl amino (C1-C5), alkyl carbamoyl (C1-C5), thiol, alkyl thio (C1-C5) or benzenoid aryl thio, cyano, nitro, haloalkyl (C1-C5), alkylsulfonyl (C1-C5), and sulfonate;

Two of such substituents can be part of a fused ring, which can be either saturated, 25 or unsaturated, heterocyclic or carbocyclic;

and natural amino acid substituents which may be attached to the compounds of formula (1) or (2) via an ester linkage to a hydroxyl group;

30 their derivatives, metabolites, analogues and/or mimic molecules with pharmaceutical acceptable additives, diluents, carriers and excipients and pharmaceutically acceptable salts thereof.

- 7 -

"Alkyl" as used herein means linked normal, secondary, tertiary or cyclic carbon atoms linear, branched or cyclic chains, saturated or unsaturated. The number of carbon atoms in an alkyl group or moiety is about 1 to about 20, unless otherwise specified, e.g. C1-10 alkyl means and alkyl moiety containing 1,2,3,4,5,6,7,8,9 or 10 carbon atoms. Substituents include but are not limited to halogen, alkyl (C1-C5), hydroxyl, alkoxy (C1-C5), alkoxycarbonyl, (C1-C5), carboxyl, amido, alkyl amido (C1-C5), amino, mono and dialkyl amino (C1-C5), alkyl carbamoyl (C1-C5), thiol, alkylthio (C1-C5) or benzenoid aryl.

"Aryl" as used herein refers to phenyl or naphthyl, or any optionally singly or multiply substituted benzenoid group (C6-C14). Substituents defined below.

"Heterocyclic" are used refers to any 4, 5 or 6 membered, optionally substituted heterocyclic ring, saturated or unsaturated, containing 1-3 ring heteroatoms, the remaining ring atoms being carbon.

In one embodiment, substituents on the aryl or heterocyclic radical may include but are not limited to: halogen, alkyl (C1-C5), hydroxyl, alkoxy (C1-C5), alkoxycarbonyl, (C1-C5), carboxyl, amido, alkyl amido (C1-C5), amino, mono and dialkyl amino (C1-C5), alkyl carbamoyl (C1-C5), thiol, alkyl thio (C1-C5) or benzenoid aryl thio, cyano, nitro, haloalkyl (C1-C5), alkylsulfonyl (C1-C5), and sulfonate.

Two of such substituents can be part of a fused ring, which can be either saturated, or unsaturated, heterocyclic or carbo cyclic.

In another embodiment, natural amino acid substituents which may be attached to the compounds of formula (1) or (2) via an ester linkage to a hydroxyl group.

In another embodiment, the compounds of the present invention are selected from the group comprising: incensole, incensole acetate, incensole oxide, incensole oxide acetate, isoincensole, isoincensole acetate, isoincensole oxide, octyl acetate, octanol, terpinyl acetate, bornyl acetate, trans-ver-benol, verbenone, menthadien-7-ol, terpinen-4-ol, trans-pinocarveol, carvone, borneol, farnesol, farnesene, β -

- 8 -

caryophyllene, humulene, β -cadinene, bergamotone, β -guaiene, β -ylangene, β -bourbonene, α -copaene, terpinene, myrcene, p -cymene, α - and β -phellandrene, α -thujene, cembrane-A, isocembrane, cembranol, cembranoids, cembranoid alcohols, furanogermacrene, furanogermacrene, germacrene, elemene, cadinene, guaiane, oplopane, eudsmene, echinodol, α -santalene, α -bisabolene, furanodiene, β -santalene, β -bergamotene, β -farnesene, β -bisabolene, SKB4, their derivatives, metabolites, analogues and/or mimic molecules with pharmaceutical acceptable additives, diluents, carriers and excipients and pharmaceutically acceptable salts thereof.

In another embodiment, the compounds of the present invention are selected from the group comprising at least one of: incensole, incensole acetate, incensole oxide, incensole oxide acetate, isoincensole, isoincensole acetate, isoincensole oxide, and/or at least one of the furanosesquiterpene furanogermacrene, their derivatives, metabolites, analogues and/or mimic molecules with pharmaceutical acceptable additives, diluents, carriers and excipients and pharmaceutically acceptable salts thereof.

In one embodiment, the composition is micronized. In accordance with the present invention, the expression "micronized" means that the composition has been micronized in accordance with any process for micronizing, a number of which are known in the art. The micronized particles preferably include a percentage of particles, which are of a diameter, which is about 10 microns, or less, preferably, 5 microns or less. For example, in a preferred aspect of the invention, at least 80% of the particles in a formulation of micronized particles have a diameter of less than 5 microns. An alternative to micronizing a compound is to solubilize the compound and put it into liposomes of appropriate size. The manufacture of liposomes and the insertion of active ingredients into such liposomes are well known in the art.

In another embodiment the composition is delivered to infected cells by incorporating the compounds of the present invention into liposomes or carbohydrate vehicles. In another embodiment, the composition is formulated into liposomes or carbohydrate vehicles.

- 9 -

In one embodiment, the liposomes or carbohydrate vehicles are specifically targeted to tumours by covalently attaching a monoclonal antibody directed to a tumour-associated antigen.

5

In one embodiment, the liposomes or carbohydrate vehicles are targeted to HIV infected cells by putting viral antibodies on its surface. In another embodiment, the viral antibodies are directed to the HIV coat protein gp160 and/or gp120.

- 10 In another embodiment, the present invention is directed to a pharmaceutical formulation comprising a composition as described herein and a pharmaceutically acceptable carrier thereof.

- 15 In one embodiment the pharmaceutically acceptable carrier, which in one embodiment is a cyclodextrin, alpha-cyclodextrin, beta-cyclodextrin, (beta-hydroxypropylcyclodextrin) gamma-cyclodextrin and in another embodiment is vitamin E oil.

- 20 The compounds of the present invention can be formulated and administered as free bases or in the form of their pharmaceutically acceptable salts for purposes of stability, convenience of crystallisation, increased solubility, and the like.

- 25 The present invention is further directed to the use of a pharmaceutical formulation for the manufacture of a medicament for treatment of a mammal suffering from a neoplasia comprising a pharmaceutical formulation as described herein.

- 30 The present invention is also directed to the use of a pharmaceutical formulation for the manufacture of a medicament for sensitising a resistant neoplasia to subsequent therapy comprising administering to a patient in need thereof a therapeutically effective amount of composition as previously described.

The present invention is directed to a method of inhibiting neoplastic cells by exposing those cells to a pharmacologically effective amount of compositions

- 10 -

containing those compounds of the present invention described below, their derivatives, metabolites, analogues and/or mimic molecules with pharmaceutical acceptable additives, diluents, carriers and excipients. Such compounds are effective at eliminating and inhibiting the growth of neoplasias such as precancerous lesions, tumours and cancer growth. One of the advantages of utilising such compositions is that they are low in toxicity, which in combination with their mechanism of action diminishes resistance development.

The present invention provides compounds, their derivatives, metabolites, analogues and/or mimic molecules with pharmaceutical acceptable additives, diluents, carriers and excipients and pharmaceutically acceptable salts thereof, as well as pharmaceutical compositions comprising the compounds of the present invention, their derivatives, metabolites, analogues and/or mimic molecules with pharmaceutical acceptable additives, diluents, carriers and excipients and methods comprising inhibiting tumour growth or treating cancer by administering one or more of the compounds of the present invention, their derivatives, metabolites, analogues and/or mimic molecules with pharmaceutical acceptable additives, diluents, carriers and excipients.

The present invention also provides products that are useful for treating neoplasia with minimal toxic side effects unlike the high toxicity associated with standard chemotherapeutic agents.

The present invention is also directed to the use of a pharmaceutical formulation for the manufacture of a medicament for treatment of a mammal suffering from an immunodysregulatory condition comprising a composition as described herein to a subject.

The present invention is also directed to providing a composition that regulates immune responses.

These and other objects of the present invention will become apparent from the description of the invention disclosed below, which descriptions are intended to limit

- 11 -

neither the spirit or scope of the invention but are only offered as illustrations of the preferred embodiments of the invention.

The present invention is directed to the treatment, inhibition and/or prevention of tumours and/or cancer growth and more particularly to treating neoplasia.

- 5 As used herein, the term "neoplasia" or neoplasm covers dysplasia, precancerous lesions, cancerous lesions, neoplastic cells, cancer, cancer growth, tumours, benign tumours, malignant tumours, solid tumours, carcinomas, etc.

- As used herein, the term "precancerous lesion" includes syndromes represented by abnormal neoplastic, including dysplastic, changes of tissue. Examples include
10 precancerous growths in colonic, breast, renal, central nervous, gastric, or lung tissues, or conditions such as dysplastic nevus syndrome, a precursor to malignant melanoma of the skin. Examples also include, in addition to dysplastic nevus syndromes, polyposis syndromes, colonic polyps, precancerous lesions of the cervix (i.e., cervical dysplasia), prostatic dysplasia, bronchial dysplasia, breast,
15 bladder and/or skin and related conditions (e.g., actinic keratosis), whether the lesions are clinically identifiable or not.

- The compounds of the present invention can be administered to a mammal having a susceptible cancer, i.e. a malignant cell population or tumour. Compounds of the present invention are effective on human tumours in vivo as well as on tumour cell
20 lines in vitro. The compounds of the present invention may be particularly useful for the treatment of solid tumours for which relatively few treatments are available. Such tumours include epidermoid and myeloid tumours, acute or chronic, nonsmall cell, squamous. Specific cancers which may be mentioned as susceptible to treatment by administration of compounds in accordance with the present invention
25 include prostate cancer, colon cancer, small cell lung cancer, large cell lung cancer, lung adenocarcinoma, epidermoid lung cancer, melanoma (including amelanotic subtypes), renal cell carcinoma, gastric carcinoma, cancers of the central nervous system (based on the likelihood that the compounds will cross the blood cell barrier) including brain tumours, neuroblastomas, gastric carcinoma, breast cancer,
30 ovarian cancer, testicular cancer, lymphoma and leukaemia, oesophageal cancer, stomach cancer, liver cancers, prostate cancer, cervical cancer, adrenal cancer,

- 12 -

oral or mucosal cancer, bladder cancer, pancreatic cancer, lymphoma, Hodgkins disease, sarcomas. Hematopoietic cell cancers such as B cell leukaemia/lymphomas, myelomas, T-cell leukemias/lymphomas, small cell leukemias/lymphomas, null cell, sezary, monocytic, myelomonocytic and Hairy cell
5 leukemias. These lymphomas/leukemias can be either acute or chronic. Other cancers may also be susceptible to treatment with the compounds of the present invention. The activity can readily be measured using standardised tests known to those skilled in the art.

As used herein, the term "carcinomas" refers to lesions that are cancerous.
10 Examples include malignant melanomas, breast cancer, and colon cancer. As used herein, the term "neoplasm" refers to both precancerous and cancerous lesions.

As used herein, the terms "inhibit" or "inhibiting," mean decreasing tumour cell growth rate from the rate that would occur without treatment and/or causing tumour
15 mass to decrease. Inhibiting also includes causing a complete regression of the tumour. Thus the compounds of the present invention can be either cytostatic or cytotoxic to the tumour cells.

As used herein, the terms subject and patient are used interchangeably. Subjects and patients are mammals.

20 The compounds of the present invention are useful antineoplastic agents i.e. to inhibit tumour cell growth in vitro and in vivo, in mammalian hosts, such as humans or domestic animals, and are particularly effective against solid tumours and multidrug resistant tumours. Thus the invention provides a method comprising inhibiting cancer cells, by contacting said cells, in vitro and in vivo with an effective
25 amount of at least one compound of the present invention. The invention also provides a therapeutic method comprising treating cancer (i.e. inhibiting tumour cell growth) by administering at least one of the compounds of the present invention to a mammal in need of such therapy.

- 13 -

The invention is directed to a method of treating tumours comprising administering a biologically active amount of a composition which consists of at least one compound of the present invention, their derivatives, metabolites, analogues and/or mimic molecules with pharmaceutical acceptable additives, diluents, carriers and excipients and pharmaceutically acceptable salts thereof.

The invention features a method of treating cancer comprising administering to a patient in need thereof a cancer treatment effective amount of a composition which consists of at least one compound of the present invention, their derivatives, metabolites, analogues and/or mimic molecules with pharmaceutical acceptable additives, diluents, carriers and excipients and pharmaceutically acceptable salts thereof.

It was surprisingly found that when a composition which consists of at least one compound of the present invention or their derivatives, metabolites, analogues or mimic molecules were administered, the proliferation of neoplastic cells was inhibited, which is manifested, pursuant to one aspect of the present invention, in a broad-spectrum anti-neoplastic activity.

The compounds of the present invention are individually diverse, but collectively all act to inhibit the propagation of neoplastic cells, cancers, cancer growth and/or tumours.

The invention also features a method of treating neoplasia comprising administering to a patient an effective amount of a composition which consists of at least one compound of the present invention and a pharmaceutically acceptable carrier.

Treating neoplasia in a patient includes achieving, partially or substantially, one or more of the following: arresting the growth or spread of a cancer, reducing the extent of a cancer (e.g., reducing size of a tumour or reducing the number of affected sites), inhibiting the growth rate of a cancer, and ameliorating or improving a clinical symptom or indicator associated with a cancer (such as tissue or serum components).

- 14 -

The present invention relates to specific compounds, defined herein, that display immuno-modulatory activity. It has been surprisingly found the compounds of the present invention have potent immuno-modulatory activity.

- 5 The present invention also relates to compositions and methods of treatment for prevention of an immunodysregulation condition.

The present invention also relates to specific compounds, defined herein, that enhance endogenous heat shock proteins (hsp) and precursor dendritic cell levels.

10

In accordance with the present invention, a method is provided to treat or prevent an immunodysregulatory condition comprising administering to a subject an effective amount of a composition which consists of at least one of the compounds of the present invention, their derivatives, metabolites, analogues and/or mimic
15 molecules with pharmaceutical acceptable additives, diluents, carriers and excipients and pharmaceutically acceptable salts thereof.

20

The present invention also provides the use of compositions which consist of one or more of the compounds of the present invention, their derivatives, metabolites, analogues and/or mimic molecules with pharmaceutical acceptable additives,
20 diluents, carriers and excipients and pharmaceutically acceptable salts thereof, for the manufacture of a medicament for an immunodysregulatory condition.

25

The present invention also provides compositions which consists of at least one compound of the present invention for use in a method of treatment of an immunodysregulatory condition, said method comprising administering one or more
25 to a subject.

30

The pharmaceutical formulations may also be administered in combination with other therapeutic treatments, such as radiation treatment, surgery or in combination with other anticancer, antiviral or antiparasite drugs. The formulations of the present invention may further include as optional ingredients one or more chemotherapeutic agents already known for their use in the inhibition of cancer cells, for added clinical

- 15 -

efficacy. Such combinations will in some cases provide added benefit.

In one embodiment, the pharmaceutical formulation further includes at least one conventional chemotherapeutic agent.

5

In another embodiment, the conventional chemotherapeutic agent is selected from the group comprising flutamide and luprolipe, antioestrogens, such as tamoxifen, antimetabolites and cytotoxic agents, such as daunorubicin, fluorouracil, floxuridine, interferon alpha, methotrexate, plicamycin, mercaptopurine, thioguanine, adramycin, 10 carmustine, lomustine, cytarabine, cyclophosphamide, doxorubicin, estramustine, altretamine, hydroxyurea, ifosfamide, procarbazine, mutamycin, busulfan, mitoxantrone, carboplatin, cisplatin, streptozocin, bleomycin, dactinomycin and idamycin, hormones such as, medroxyprogesterone, estramustine, ethinyl oestradiol, oestradiol, leuprolide, megestrol, octreotide, diethylstilbestrol, 15 chlorotrianisene, etoposide, podophyllotoxin, and goserelin, nitrogen mustard derivatives such as, melphalan, chlorambucil, methlorethamine and thiotepa, steroids such as, betamethasone, and other antineoplastic agents such as live *Mycobacterium bovis*, dicarbazine, asparaginase, leucovorin, mitotane, vincristine, vinblastine and texotere, cyclophosphamide, adriamycin, 5-fluorouracil, 20 hexamethylmelamine, Acivicin; Aclarubicin; Acodazole Hydrochloride; AcrQnine; Adozelesin; Aldesleukin; Altretamine; Ambomycin; Ametantrone Acetate; Aminoglutethimide; Amsacrine; Anastrozole; Anthramycin; Asparaginase; Asperlin; Azacitidine; Azetepa; Azotomycin; Batimastat; Benzodepa; Bicalutamide; Bisantrene Hydrochloride; Bisnafide Dimesylate; Bizelesin; Bleomycin Sulfate; 25 Brequinar Sodium; Bropiramine; Busulfan; Cactinomycin; Calusterone; Caracemide; Carbetimer; Carboplatin; Carmustine; Carubicin Hydrochloride; Carzelesin; Cedefingol; Chlorambucil; Cirolemycin; Cisplatin; Cladribine; Crisnatol Mesylate; Cyclophosphamide; Cytarabine; Dacarbazine; Dactinomycin; Daunorubicin Hydrochloride; Decitabine; Dexormaplatin; Dezaguanine; Dezaguanine Mesylate; 30 Diaziquone; Docetaxel; Doxorubicin; Doxorubicin Hydrochloride; Droloxifene; Droloxifene Citrate; Dromostanolone Propionate; Duazomycin; Edatrexate; Eflomithine Hydrochloride; Elsamitucin; Enloplatin; Enpromate; Epiropidine; Epirubicin Hydrochloride; Erbulozole; Esorubicin Hydrochloride; Estramustine;

- 16 -

- Estramustine Phosphate Sodium; Etanidazole; Ethiodized Oil I 131; Etoposide;
 Etoposide Phosphate; Etoprine; Fadrozole Hydrochloride; Fazarabine; Fenretinide;
 Floxuridine; Fludarabine Phosphate; Fluorouracil; Flurocitabine; Fosquidone;
 Fostriecin Sodium; Gemcitabine; Gemcitabine Hydrochloride; Gold Au 198;
 5 Hydroxyurea; Idarubicin Hydrochloride; Ifosfamide; Ilmofofosine; Interferon Alfa-2a;
 Interferon Alfa-2b; Interferon Alfa-n1; Interferon Alfa-n3; Interferon Beta- I a;
 Interferon Gamma- I b; Iproplatin; Irinotecan Hydrochloride; Lanreotide Acetate;
 Letrozole; Leuprolide Acetate; Liarozole Hydrochloride; Lometrexol Sodium;
 Lomustine; Losoxantrone Hydrochloride; Masoprocol; Maytansine;
 10 Mechlorethamine Hydrochloride; Megestrol Acetate; Melengestrol Acetate;
 Melphalan; Menogaril; Mercaptopurine; Methotrexate; Methotrexate Sodium;
 Metoprine; Meturedopa; Mitindomide; Mitocarcin; Mitocromin; Mitogillin; Mitomalcin;
 Mitomycin; Mitosper; Mitotane; Mitoxantrone Hydrochloride; Mycophenolic Acid;
 Nocodazole; Nogalamycin; Ormaplatin; Oxisuran; Paclitaxel; Pegaspargase;
 15 Peliomycin; Pentamustine; Peplomycin Sulfate; Perfosfamide; Pipobroman;
 Pipsulfan; Piroxantrone Hydrochloride; Plicamycin; Plomestane; Porfimer Sodium;
 Porfiromycin; Prednimustine; Procarbazine Hydrochloride; Puromycin; Puromycin
 Hydrochloride; Pyrazofurin; Riboprine; Rogletimide; Safmgol; Safingol
 Hydrochloride; Semustine; Simtrazene; Sparfosate Sodium; Sparsomycin;
 20 Spirogermanium Hydrochloride; Spiromustine; Spiroplatin; Streptonigrin;
 Streptozocin; Strontium Chloride Sr 89; Sulofenur; Talisomycin; Taxane; Taxoid;
 Tecogalan Sodium; Tegafur; Teloxantrone Hydrochloride; Temoporfin; Teniposide;
 Teroxirone; Testolactone; Thiamiprine; Thioguaninē; Thiotepa; Tiazofurin;
 Tirapazamine; Topotecan Hydrochloride; Toremifene Citrate; Trestolone Acetate;
 25 Triciribine Phosphate; Trimetrexate; Trimetrexate Glucuronate; Triptorelin;
 Tubulozole Hydrochloride; Uracil Mustard; Uredopa; Vapreotide; Verteporfin;
 Vinblastine Sulfate; Vincristine Sulfate; Vindesine; Vindesine Sulfate; Vinepidine
 Sulfate; Vinglycinate Sulfate; Vinleurosine Sulfate; Vinorelbine Tartrate; Vinrosidine
 Sulfate; Vinzolidine Sulfate; Vorozole; Zeniplatin; Zinostatin; Zorubicin
 30 Hydrochloride, 20-epi-1,25 dihydroxyvitamin D3; 5-ethynyluracil; abiraterone;
 aclarubicin; acylfulvene; adecypenol; adozelesin; aldesleukin; ALL-TK antagonists;
 altretamine; ambamustine; amidox; amifostine; aminolevulinic acid; amrubicin;
 atrsacrine; anagrelide; anastrozole; andrographolide; angiogen sis inhibitors;

- 17 -

antagonist D; antagonist G; DHEA; bromineepiandrosterone; epiandrosterone; antarelix; anti-dorsalizing morphogenetic protein-1; antiandrogen, prostatic carcinoma; antiestrogen; antineoplaston; antisense oligonucleotides; aphidicolin glycinate; apoptosis gene modulators; apoptosis regulators; apurinic acid; ara-
5 CDP-DL-PTBA; arginine deaminase; asulacrine; atamestane; atrimustine; axinastatin 1; axinastatin 2; axinastatin 3; azasetron; azatoxin; azatyrosine; baccatin III derivatives; balanol; batimastat; BCR/ABL antagonists; benzochlorins; benzoylstauroporine; beta lactam derivatives; beta-alethine; betaclamycin B; betulinic acid; bFGF inhibitor; bicalutamide; bisantrene; bisaziridinylspermine;
10 bisnafide; bistratene A; bizelesin; breflate; bropirimine; budotitane; buthionine sulfoximine; calcipotriol; calphostin C; camptothecin derivatives; canarypox IL-2; capecitabine; carboxamide-amino-triazole; carboxyamidotriazole; CaRest M3; CARN 700; cartilage derived inhibitor; carzelesin; casein kinase inhibitors (ICOS); castanospermine; cecropin B; cetrorelix; chlorins; chloroquinoxaline sulfonamide;
15 cicaprost; cis-porphyrin; cladribine; clomifene analogues; clotrimazole; collismycin A; collismycin B; combretastatin A4; combretastatin analogue; conagenin; crambescidin 816; crisnatol; cryptophycin 8; cryptophycin A derivatives; curacin A; cyclopentantraquinones; cycloplatan; cypemycin; cytarabine ocfosfate; cytolytic factor; cytostatin; dacliximab; decitabine; dehydrodidemnin B; deslorelin;
20 dexifosfamide; dexrazoxane; dexverapamil; diaziquone; didemnin B; didox; diethylnorspermine; dihydro-5-azacytidine; dihydrotaxol, 9-; dioxamycin; diphenyl spiromustine; docosanol; dolasetron; doxifluridine; droloxifene; dronabinol; duocannycin SA; ebselen; ecomustine; edelfosine; edrecolomab; eflornithine; elemene; emitefur; epirubicin; epristeride; estramustine analogue; estrogen
25 agonists; estrogen antagonists; etanidazole; etoposide phosphate; exemestane; fadrozole; fazarabine; fenretinide; filgrastim; fmasteride; flavopiridol; flezelastine; fluasterone; fludarabine; fluorodaunorubicin hydrochloride; forfenimex; formestane; fostriecin; fotemustine; gadolinium texaphyrin; gallium nitrate; galocitabine; ganirelix; gelatinase inhibitors; gemcitabine; glutathione inhibitors; hepsulfam;
30 heregulin; hexamethylene bisacetamide; hypericin; ibandronic acid; idarubicin; idoxifene; idramantone; ilmofosine; ilomastat; imidazoacridones; imiquimod; immunostimulant peptides; insulin-like growth factor-1 receptor inhibitor; interferon agonists; interf rons; interleukins; iobenguane; iododoxorubicin; ipomeanol, 4-;

- 18 -

- irinotecan; iroplact; irsogladine; isobengazole; isohomohalicondrin B; itasetron; jaspilakinolide; kahalalide F; lamellarin-N triacetate; lanreotide; leinamycin; lenograstim; lentinan sulfate; leptolstatin; letrozole; leukemia inhibiting factor; leukocyte alpha interferon; leuprolide+estrogen+progesterone; leuprorelin;
- 5 levamisole; liarozole; linear polyamine analogue; lipophilic disaccharide peptide; lipophilic platinum compounds; lissoclinamide 7; lobaplatin; lombricine; lometrexol; lonidamine; losoxantrone; lovastatin; loxoribine; lurtotecan; lutetium texaphyrin; lysofylline; lytic peptides; maitansine; mannostatin A; marimastat; masoprocol; maspin; matrilysin inhibitors; matrix metalloproteinase inhibitors; menogaril;
- 10 merbarone; meterelin; methioninase; metoclopramide; MIF inhibitor; mifepristone; miltefosine; mirimostim; mismatched double stranded RNA; mitoguazone; mitolactol; mitomycin analogues; mitonafide; mitotoxin fibroblast growth factor-saporin; mitoxantrone; mofarotene; molgramostim; monoclonal antibody, human chorionic gonadotrophin; monophosphoryl lipid A +myobacterium cell wall sk;
- 15 mopidamol; multiple drug resistance gene inhibitor; multiple tumor suppressor 1-based therapy; mustard anticancer agent; mycaperoxide B; mycobacterial cell wall extract; myriaporone; N-acetyldinaline; N-substituted benzamides; nafarelin; nagrestip; naloxone +pentazocine; napavin; naphterpin; nartograstim; nedaplatin; nemorubicin; neridronic acid; neutral endopeptidase; nilutamide; nisamycin; nitric
- 20 oxide modulators; nitroxide antioxidant; nitrullyn; O6-benzylguanine; octreotide; okicenone; oligonucleotides; onapristone; ondansetron; ondansetron; oracin; oral cytokine inducer; ormaplatin; osaterone; oxaliplatin; oxaunomycin; paclitaxel analogues; paclitaxel derivatives; palauamine; palmitoylrhizoxin; pamidronic acid; panaxytriol; panomifene; parabactin; pazelliptine; pegaspargase; peldesine;
- 25 pentosan polysulfate sodium; pentostatin; pentozole; perflubron; perfosfamide; perillyl alcohol; phenazinomycin; phenylacetate; phosphatase inhibitors; picibanil; pilocarpine hydrochloride; pirarubicin; piritrexim; placetin A; placetin B; plasminogen activator inhibitor; platinum complex; platinum compounds; platinum-triamine complex; porfimer sodium; porfiromycin; propyl bis-acridone; prostaglandin
- 30 J2; proteasome inhibitors; protein A-based immune modulator; protein kinase C inhibitor; protein kinase C inhibitors, microalgal; protein tyrosine phosphatase inhibitors; purine nucleoside phosphorylase inhibitors; purpurins; pyrazoloacridine; pyridoxylated hemoglobin polyoxyethylene conjugate; raf antagonists; raltitrexed;

- 19 -

ramosetron; ras farnesyl protein transferase inhibitors; ras inhibitors; ras-GAP inhibitor; retelliptine demethylated; rhenium Re 186 etidronate; rhizoxin; ribozymes; RII retinamide; rogletimide; rohitukine; romurtide; roquinimex; rubiginone B1; ruboxyl; safingol; saintopin; SarCNU; sarcophytol A; sargramostim; Sdi 1 mimetics; semustine; senescence derived inhibitor 1; sense oligonucleotides; signal transduction inhibitors; signal transduction modulators; single chain antigen binding protein; sizofiran; sobuzoxane; sodium borocaptate; sodium phenylacetate; solverol; somatomedin binding protein; sonermin; sparfosic acid; spicamycin D; spiromustine; splenopentin; spongistatin 1; squalamine; stem cell inhibitor; stem-cell division inhibitors; stipiamide; stromelysin inhibitors; sulfmosine; superactive vasoactive intestinal peptide antagonist; suradista; suramin; swainsonine; synthetic glycosaminoglycans; tallimustine; tamoxifen methiodide; tauromustine; tazarotene; tecogalan sodium; tegafur; tellurapyrylium; telomerase inhibitors; temoporfin; temozolomide; teniposide; tetrachlorodecaoxide; tetrazomine; thaliblastine; thalidomide; thiocoraline; thrombopoietin; thrombopoietin mimetic; thymalfasin; thymopoietin receptor agonist; thymotrinan; thyroid stimulating hormone; tin ethyl etiopurpurin; tirapazamine; titanocene dichloride; topotecan; topsentin; toremifene; totipotent stem cell factor; translation inhibitors; tretinoin; triacetyluridine; triciribine; trimetrexate; triptorelin; tropisetron; turosteride; tyrosine kinase inhibitors; tyrphostins; UBC inhibitors; ubenimex; urogenital sinus-derived growth inhibitory factor; urokinase receptor antagonists; vapreotide; variolin B; vector system, erythrocyte gene therapy; velaresol; venom, anti-venom, veramine; verdins; verteporfin; vinorelbine; vinxaltine; vitaxin; vorozole; zanoterone; zeniplatin; zilascorb; zinostatin stimalamer, immunostimulating drugs or therapeutic agents, their metabolites, salts and derivatives thereof.

In one embodiment, the composition further includes at least one anti-viral agent.

In one embodiment, the anti-viral agents are selected from the group comprising nucleoside analogues (AZT; ddC; ddi; d4T; 3TC; BW 1592; PMEA/bis-POM PMEA; dOTC; DAPD); non-nucleoside reverse transcriptase inhibitors (delavirdine; DMP 266; HBY097; loviride; nevirapine, emivirine; AG1549; PNU142721; Calanolide A; DPC961); protease inhibitors (ABT-378; ritonavir; nelfinavir; BW 141; KNI-272;

- 20 -

indinavir; saquinavir; L-756,423; DMP-450; BMS-232630); ALX40-4C; hydroxyurea; lobucavir; pentafuside; T-1249; PRO 542; FP-21399; AMD 3100; HE-2000 and peptide T; Abacavir; Acemannan; Acyclovir; Acyclovir Sodium; Adefovir; Alovudine; Alvircept Sudotox; Amantadine Hydrochloride; Aranotin; Arildone; Atevirdine

5 Mesylate; Avridine; Cidofovir; Cipamfylline; Coviracil; Cytarabine Hydrochloride; Delavirdine Mesylate; Desciclovir; Didanosine; Disoxaril; Edoxudine; Emivirine; Emtricitabine; Envirodene; Enviroxime; Epivir; Famciclovir; Famotidine Hydrochloride; Fiacitabine; Fialuridine; Fosarilate; Foscamet Sodium; Fosfonet Sodium; Ganciclovir; Ganciclovir Sodium; Idoxuridine; Indinavir; Kethoxal;

10 Lamivudine; Lobucavir; Lodenosine; Lopinavir, Memotidine Hydrochloride; Methisazone; Nelfinavir; Nevirapine; Penciclovir; Pirodavid; Ribavirin; Rimantadine Hydrochloride; Saquinavir Mesylate; Ritonavir; Somantadine Hydrochloride; Sorivudine; Statolon; Stavudine; Tenofovir; Tilorone Hydrochloride; Trifluridine; Valacyclovir Hydrochloride; Vidarabine; Vidarabine Phosphate; Vidarabine Sodium

15 Phosphate; Tipranavir, Viroxime; Zalcitabine; Zidovudine; Zinviroxime and Interferon.

In one embodiment, the composition further includes at least one anti-parasite agent.

20

In one embodiment, the anti-parasite agents are selected from the group comprising chloroquin, primaquine, mefloquine, pyrimethamine-sulfadoxone, atoraquone/dapsone; halofantrine; artemisinin derivatives; atoraquone + proguanil, co-artemether; podophyllotoxin; pentamidine, diloxanide furoate, metronidazole,

25 tindazole, tetracycline, quinacrine, stibogluconate, amphotericin B, quinine, doxycycline, trimethoprim-sulfamethoxazole, metronidazole, nifurtimox, suramin, melarsoprol, benznidazole, their metabolites, salts derivatives or any other anti-parasitic agent thereof.

30

The agents of the present invention may also be administered in combination with other agents for example immunostimulating drugs or therapeutic agents. Appropriate amounts in each case will vary with the particular agent, and will be either readily known to those skilled in the art or readily determinable by routine

- 21 -

experimentation.

In one embodiment, the pharmaceutical formulation is administered in combination with radiation treatment.

5

In one embodiment, the pharmaceutical formulation is administered in combination with surgery.

10 The invention also relates to a method of suppressing tumour growth in a mammal by administering to the mammal an amount of a composition which consists of at least one of the compounds of the present invention, derivatives, metabolites, analogues and/or mimic molecules, and a second chemotherapeutic agent effective to suppress tumour growth in the mammal. The second chemotherapeutic agent is not a compound of the present invention or a derivative, metabolite, analogue or
15 mimic molecule. These compositions provide enhanced antitumour effect and may also prevent the development of metastases. In particular, these compounds are useful for overcoming tumours that are drug resistant. These agents may be administered separately or as a cocktail. Toxicity may be reduced by administering the compound of the present invention or a derivative, metabolite, analogue or
20 mimic molecule, thereof several hours prior to administering the chemotherapeutic agent. The compositions can be administered by any route.

The components of any of the pharmaceutical formulations disclosed herein can be administered simultaneously (in a combination formulation), essentially
25 simultaneously (e.g., administration of each compound a few minutes or a few hours apart), or can be administered sequentially, e.g., several days apart, or more than a week apart. For example, a compound of the present invention, (and a conventional chemotherapeutic agent) can be administered together, or essentially simultaneously, e.g., administration of each compound a few minutes or a few
30 hours apart, or can be administered sequentially, e.g., several days apart, or more than a week apart. All such variations in administration of the combination therapy are encompassed within the scope of the invention.

- 22 -

In one embodiment, the neoplasia is a precancerous lesion including syndromes represented by abnormal neoplastic and/or dysplastic, changes of tissue comprising precancerous growths in colonic, breast, renal, central nervous, gastric, or lung tissues, or conditions such as dysplastic nevus syndrome, a precursor to malignant melanoma of the skin, dysplastic nevus syndromes, polyposis syndromes, colonic polyps, precancerous lesions of the cervix (i.e., cervical dysplasia), prostatic dysplasia, bronchial dysplasia, breast, bladder and/or skin and related conditions (e.g., actinic keratosis), whether the lesions are clinically identifiable or not.

In one embodiment, the neoplasia is prostate cancer, colon cancer, small cell lung cancer, large cell lung cancer, lung adenocarcinoma, epidermoid lung cancer, melanoma (including amelanotic subtypes), renal cell carcinoma, gastric carcinoma, cancers of the central nervous system including brain tumours, neuroblastomas, gastric carcinoma, breast cancer, ovarian cancer, testicular cancer, lymphoma and leukaemia, oesophageal cancer, stomach cancer, liver cancers, prostate cancer, cervical cancer, adrenal cancer, oral or mucosal cancer, bladder cancer, pancreatic cancer, lymphoma, Hodgkins disease, sarcomas. Hematopoietic cell cancers such as B cell leukaemia/lymphomas, myelomas, T-cell leukemias/lymphomas, small cell leukemias/lymphomas, null cell, sezary, monocytic, myelomonocytic and Hairy cell leukemias.

In one embodiment, the neoplasia is in the form of a tumour comprising an epidermoid and myeloid tumour, acute or chronic, nonsmall cell, squamous or solid.

It has been surprisingly found that the compounds of the present invention have potent immuno modulatory effects. Accordingly, the disclosed compounds of the present invention when administered to human patients will have a broad immuno-modulatory effect, resulting in its application in many syndromes, especially following treatment for or infection by cancerous cells. More specifically, one aspect of the present invention relates to the use of the compounds of the present invention in treatment of an immunodysregulation condition.

- 23 -

According to one aspect of the invention, a composition containing at least one of the compounds of the present invention enhance the production of endogenous heat shock protein (hsp) production, regardless of the immunocompetency of the individual. According to another aspect of the invention, a composition containing at least one of the compounds of the present invention enhance levels of precursor dendritic cells.

The advantage of administering a pharmaceutical formulation containing at least one compound of the present invention with a suitable carrier is three fold:

1. The cancer-infected cell is presented to the immune system where its presence is detected due to enhanced immunosurveillance.
2. The compounds of the present invention have immuno up-regulatory properties, precursor dendritic and natural killer cells are up regulated. Antigen capture is further enhanced by a domino effect of increasing precursor dendritic cell maturation into cytotoxic T cells.
3. The presentation of the antigenic peptides to the cytotoxic T cells is improved.

In one embodiment, a pharmaceutical formulation is provided to enhance endogenous hsp levels, comprising administering to a patient in need thereof a therapeutically effective amount of a composition comprising at least one compound of the present invention.

In another embodiment, a method for enhancing endogenous hsp levels in a living subject is provided, comprising administering to a patient in need thereof a therapeutically effective amount of a composition comprising at least one compound of the present invention.

In another embodiment, a method of treating the symptoms of low levels of endogenous hsp levels in a living subject is provided, comprising administering to a patient in need thereof a therapeutically effective amount of a composition comprising at least one compound of the present invention.

- 24 -

In another embodiment, a pharmaceutical formulation is provided to enhance endogenous precursor dendritic cell levels, comprising administering to a patient in need thereof a therapeutically effective amount of a composition comprising at least one compound of the present invention.

5

Additionally, the invention provides use of the composition to provide protection against infections in immunocompromised animals and humans. These compositions may be used prophylactically or therapeutically to protect animals or patients from the consequences of infection by pathogens.

10

Further, the invention provides use of the composition in veterinary medicine, prophylactically and therapeutically in animal populations that are subject to infection that compromises immune response and cause infection.

15

In another aspect of the invention, the use of a pharmaceutical formulation is provided for the manufacture of a medicament for the treatment of a mammal suffering from an immuno dysregulation condition, comprising administering to a patient in need thereof a therapeutically effective amount of a pharmaceutical formulation of the present invention.

20

In one embodiment, the immuno dysregulation condition is caused by a viral infection, intracellular bacterial infection, extracellular bacterial infection, fungal infection, yeast infection, extracellular parasite infection, intracellular parasite infection, protozoan parasite, multicellular parasite, autoimmune disease,

25

immunosuppressive therapy, chemotherapy, anti-infective agent therapy, wound, burn, the presence of an immunosuppressive molecule, gastrointestinal irritation or any combination of the foregoing and is selected from (a) a DNA virus infection or an RNA virus (b) a parasite infection, a *Trypanosoma*, *Plasmodium*, *Cryptosporidium*, *Entamoeba*, *Balantidium*, *Leishmania*, *Pneumocystis*,

30

Trichomoniasis or *Toxoplasma* infection, wherein the *Trypanosoma*, *Plasmodium*, *Cryptosporidium*, *Entamoeba*, *Balantidium*, *Leishmania*, *Pneumocystis*, *Trichomoniasis* or *Toxoplasma* infection is selected from but not limited to *Trypanosoma cruzi*, *Trypanosoma brucei*, *Trypanosoma gambiense*, *Trypanosoma*

- 25 -

rhodesiense, *Plasmodium falciparum*, *Plasmodium vivax*, *Plasmodium malariae*,
Plasmodium ovale, *Plasmodium berghei*, *Entamoeba histolytica*, *Balantidium coli*,
Leishmania braziliensis, *Leishmania mexicana*, *Leishmania donovani*, *Leishmania*
tropica, *Pneumocystis carinii*, *Trichomoniasis vaginalis*, and *Toxoplasma gondii* (c)
5 a mycoplasma infection, a *Listeria* infection or a *Mycobacterium* infection; (d) a
Streptococcus infection, a *Staphylococcus* infection, a *Vibrio* infection, a
Salmonella infection; a *Shigella* infection, an enterotoxigenic, enteropathogenic,
enteroinvasive or enterohemorrhagic *E. coli* infection, a *Yersinia* infection, a
Campylobacter infection, a *Pseudomonas* infection, a *Borrelia* infection, a
10 *Legionella* infection and a *Haemophilus* infection; (e) pulmonary *Aspergilliosis*,
mucosal or oropharyngeal candidiasis and juvenile paracoccidiomycosis; (f) a
Candida infection and a *Cryptococcus* infection; (g) systemic lupus erythematosus,
arthritis, asthma, and diabetes (h) adriamycin treatment, cisplatin treatment,
mitomycin C treatment, amphotericin B treatment; (i) a gamma-radiation
15 treatment; (j) nucleoside analog treatment for viral infection or for cancer; (k)
surgical and accidental wounds, septic shock caused by surgery; (l) cyclosporin
treatment and corticosteroid treatment; (m) irritable bowel treatment, Crohn's
disease, wasting syndrome, cachexia, Motor Neuron disease, Multiple Sclerosis,
inflammatory bowel disease, respiratory distress syndrome, chronic diarrhoea; (n)
20 cancer; (o) cirrhosis; (p) gram positive multi-drug resistant bacteria or (q) any
combination of (a) through (p).

In one embodiment, the DNA virus infection or the RNA virus infection is selected
from a retrovirus infection, a togavirus infection, a flavivirus infection, a rubivirus
25 infection, a pestivirus infection, a lipid envelope virus infection, a filovirus, a
picornavirus infection, a rhinovirus infection, a coronavirus infection, a respiratory
syncytial virus infection, a poliovirus infection, a parainfluenza virus infection,
influenza virus infection, hantavirus, adeno-associated virus, measles virus,
poxvirus, filovirus, human papilloma virus and animal papilloma virus infection.

30

In one embodiment, the composition enhances endogenous hsp levels.

In one embodiment, the composition enhances endogenous precursor dendritic cell

- 26 -

levels.

The invention also relates to a method for reducing the immunodepressive effect of a chemotherapy agent in a mammal by administering to a mammal an amount of a composition which consists of at least one compound of the present invention or a derivative, metabolite, analogue or mimic molecule thereof effective to augment the immune system of the mammal upon treatment of the mammal with the chemotherapeutic agent. The immune system may be augmented, for example, by increasing the total number of leukocytes, T-lymphocytes, B-lymphocytes, or immunoglobulins.

The present invention also provides a method of sensitizing a neoplasia to subsequent treatment, for example radiation or chemotherapy. It is known that cancer cells become resistant to some chemotherapeutic agents and are even resistant to many different chemotherapeutic agents. This is a significant to many different chemotherapeutic treatments. This method includes administering an effective amount of a composition which consists of at least one compound of the present invention or a derivative, metabolite, analogue or mimic molecule thereof to a mammal having cancer.

In another aspect of the invention, the use of a pharmaceutical formulation is provided for the manufacture of a medicament for sensitising a resistant neoplasia to subsequent therapy comprising administering to a patient in need thereof a therapeutically effective amount of a pharmaceutical formulation of the present invention.

The method of the present invention is useful in sensitizing desensitized cancer cells in particular: ovarian, sarcoma, non-Hodgkin's lymphoma, lung, breast cancer, bladder carcinoma, colon carcinoma, pancreatic carcinoma, carcinoma of the ampulla of Vater, multiple myeloma, adult acute lymphocytic leukemia, adult non-lymphocytic leukemia and neuroblastoma. It is preferred that the cancer cells be breast cancer, multiple myeloma, ovarian or lung.

It is realized that the desensitized cancer cells may be desensitized to more than one chemotherapeutic agent. If so, the method of the present invention will

- 27 -

sensitize the desensitized cancer cells to most of the chemotherapeutic agents to which they are desensitized.

In one embodiment, the chemotherapeutic agents to which the cancer cells
 5 become desensitized are selected from the group consisting of doxorubicin, daunomycin, vinca alkaloids, vincristine, vinblastine, taxol, colchicine, epipodophyllotoxins such as etoposide, actinomycin D, puromycin, emetine, melphalan, adozelesin,
 [S-(R,R)] 6,6'-[carbonylbis(imino-1H-indole-05,2-diylcarbonyl)]bis[8-(chloromethyl)
 10 3,6,7,8-tetrahydro-1-,methyl-benzo[1,2-b:4,3-b']dipyrrol-4-l, (S)-N-[2-[[1-(chloromethyl)-1,6-dihydro-8-methyl-5-[(phenylamino)carbonyl]opxy]benzo[1,2-b:4,3-b']dipyrrol-3(2H)-yl]carbonyl]-1H-indol-5-yl]-6-(diethylamino)-2 benzofurancarboxamide, (7bR, 8aS)-7-[[1,6-dihydro-4-hydroxy-5-methoxy-7-[(4,5,8,8a-tetrahydro-7-methyl-4-oxocyclopropa[c]pyrrolo [3,2-e] indol-2(1H)-yl)carbonyl]benzo[1,2-b:4,3-b']dipyrrol-3(2H)-yl]carbonyl]-1,6-dihydro-4-hydroxy-5-methoxybenzo[1,2-b:4,3-b']dipyrrole-3(2H)-carboxamide.
 15

It is realized that new chemotherapeutic agents against cancer will be developed after this invention. The new chemotherapeutic agents to which resistance
 20 develops and which can be treated by the method of this invention are equivalent to those set forth in this invention.

In one embodiment, the pharmaceutical formulation has an enteric coating. In one embodiment, the enteric coating is made of a polymer or copolymer. In one
 25 embodiment, the polymer or copolymer is selected from the group consisting of poly(lactic-glycolic acid) polyester, cellulose acetate phthalate, hydroxypropyl-methyl cellulose phthalate poly(butyl methacrylate), (2-dimethyl aminoethyl) methacrylate, and methyl methacrylate.

30 The pharmaceutical formulation according to the present invention can be administered to a patient in any of a wide range of routes. Thus, with regard to the types of formulations in which the active compounds according to the present invention can be administered, as well as any additives can be included with the

- 28 -

active compounds in the formulations, and the possible routes of administration, it is well known to those of skill in the art that such formulations can be provided in a wide variety of types, and it is within the skill of the ordinary artisans to select a specific formulation and route of administration and then test suitability for use. By way of example but not limitation, suitable routes include enteric, parenteral, topical, oral, rectal, nasal or vaginal routes. Parenteral routes include subcutaneous, intramuscular, intravenous, intraperitoneal, intradermal and sublingual administration. Also, compositions may be implanted into a patient or injected using a drug delivery system.

The pharmaceutical formulation according to the present invention may be administered locally or systemically. By systemic administration means any mode or route of administration that results in effective amounts of active ingredient appearing in the blood or at a site remote from the route of administration of the active ingredient.

Further, the pharmaceutical formulation according to the present invention may be administered intermittently. The advantage of this is that it allows the patient to suspend therapy for periods without the worry of inactivity of the drug resulting from the development of resistant cells.

The pharmaceutical formulation according to the invention may be formulated for enteral, parenteral or topical administration. Indeed all three types of formulations may be used simultaneously to achieve systemic administration of the active ingredient.

Compounds useful in the methods of this invention may be formulated into compositions together with pharmaceutically acceptable carriers for oral administration in solid or liquid form, or for rectal administration, although carriers for oral administration are most preferred.

Pharmaceutically acceptable carriers for oral administration include capsules, tablets, pills, powders, troches and granules. In such solid dosage forms, the

- 29 -

carrier can comprise at least one inert diluent such as sucrose, lactose or starch. Such carriers can also comprise, as is normal practice, additional substances other than diluents, e.g., lubricating agents such as magnesium stearate. In the case of capsules, tablets, troches and pills, the carriers may also comprise buffering agents. Carriers such as tablets, pills and granules can be prepared with enteric coatings on the surfaces of the tablets, pills or granules. Alternatively, the enterically coated compound can be pressed into a tablet, pill, or granule, and the tablet, pill or granules for administration to the patient. Preferred enteric coatings include those that dissolve or disintegrate at colonic pH such as shellac or Eudraget S. Additional pharmaceutically acceptable carriers include liquid dosage forms for oral administration, e.g. pharmaceutically acceptable emulsions, solutions, suspensions, syrups and elixirs containing inert diluents commonly used in the art, such as water. Besides such inert diluents, compositions can also include adjuvants such as wetting agents, emulsifying and suspending agents, and sweetening, flavouring and perfuming agents.

Pharmaceutically acceptable carriers for rectal administration are preferably suppositories that may contain, in addition to the compounds of the present invention, excipients such as cocoa butter or a suppository wax.

Suitable injectable solutions include intravenous, subcutaneous and intramuscular injectable solutions. Examples of injectable forms include solutions, suspensions and emulsions. Typically the compound(s) is injected in association with a pharmaceutical carrier such as normal saline, Ringers solution, dextrose solution and other aqueous carriers known in the art. Appropriate non-aqueous carriers may also be used and examples include cyclodextrin, preferably hydroxypropyl beta cyclodextrin, mixed oils (vitamin E oil), polyethylene glycol and ethyl oleate. A preferred carrier is cyclodextrin in water. Frequently, it is desirable to include additives in the carrier such as buffers and preservatives or other substances to enhance isotonicity and chemical stability.

The composition can also be administered topically. Suitable formulations for topical administration include creams, gels, jellies, muclriages, pastes and ointments. The

- 30 -

compounds may be formulated for transdermal administration, for example in the form of transdermal patches so as to achieve systemic administration.

The composition may also be administered in the form of an implant.

5

The composition may also be administered in the form of an infusion solution or as a nasal inhalation, aerosol or spray.

10 In another embodiment, the composition is incorporated in a pharmaceutically acceptable carrier, diluents, vehicles and the like for systemic administration by feeding. An example of such a carrier is cyclodextrin (α -cyclodextrin, β -hydroxypropylcyclodextrin or γ -cyclodextrin).

15 In one embodiment, the pharmaceutical formulation is administered enterally, parenterally, topically, orally, sub-lingually, rectally, nasally or vaginally.

In one embodiment, the pharmaceutical formulation is administered to a mammal. In one embodiment, said mammal is a neonate and said administering is effected prior to delivery of said neonate and/or during delivery of said neonate.

20

The pharmaceutically acceptable carrier and compounds of this invention are formulated into unit dosage forms for administration to a patient. The dosage levels of active ingredient (i.e. compounds of this invention) in the unit dosage may be varied so as to obtain an amount of active ingredient effective to achieve lesion-eliminating activity in accordance with the desired method of administration (i.e., oral or rectal). The selected dosage level therefore depends upon the nature of the active compound administered, the route of administration, the desired duration of treatment, individual needs and other factors. If desired, the unit dosage may be such that the daily requirement for active compound is in one dose, or divided among multiple doses for administration, e.g., two to four times per day.

25

With regard to dosage and duration of treatment according to any aspect of the present invention, it is recognized that the ability of an artisan skilled in

- 31 -

pharmaceutical administration of drugs to determine suitable dosages depending on many inter-related factors is well known, and skilled artisans are readily able to monitor patients to determine whether treatment should be started, continued, discontinued or resumed at any given time. For example, dosages of the compounds are suitably determined depending on the individual cases taking symptoms, age and sex of the subject and the like into consideration. The amount of the compound to be incorporated into the pharmaceutical composition of the invention varies with dosage route, solubility of the compound, administration route, administration scheme and the like. An effective amount for a particular patient may vary depending on factors such as the condition being treated, the overall health of the patient and the method, route and dose of administration. The clinician using parameters known in the art makes determination of the appropriate dose. Generally, the dose begins with an amount somewhat less than the optimum dose and it is increased by small increments thereafter until the desired or optimum effect is achieved. Suitable dosages can be determined by further taking into account relevant disclosure in the known art. In one embodiment, the unit dose comprises 5-500 mg of active ingredient consisting of at least one compound of the present invention.

The pharmaceutical formulations of this invention are preferably packaged in a container (e.g. a box or bottle, or both) with suitable printed material (e.g. a package insert) containing indications, directions for use, etc.

The present invention is also directed to compositions which consist of at least one compound if the present invention acting as prodrug compounds analogous to the active compounds disclosed herein. Such compounds are generally themselves inactive or low in activity, but are converted into active compounds. Thus, for example, pro-drugs such as the methyl ester of any acid functionality, which is not active *per se* or has very low activity could be hydrolysed, either uncatalytically or catalytically with an enzyme such as an esterase, to an active compound. Such pro-drug compounds could well be the preferred therapeutic form of the present compounds. These analogous prodrugs can be produced from active compounds

- 32 -

based on procedures and factors that are well known to one of ordinary skill in the art. Accordingly as used in the present application, "pro-drug analogue" means "a chemical which is relatively non-toxic and pharmacologically inert but which can be transformed *in vivo* to a pharmacologically active drug". More specifically it means

5 a derivative, metabolite or analogue of the compounds of the present invention which have low or no ability as anti-neoplastic agents until converted in the body to a derivative, metabolite or analogue with such ability or abilities. Such pro-drugs should have favourable properties such as enhanced absorption, water solubility, lower toxicity, or better targeting to the tumour cell (such as by reason of greater

10 affinity to the tumour cell or a larger quantity of activating enzyme in the tumour cell as opposed to a normal cell so that larger concentrations of the active compound are produced in the tumour cell). Examples of such compounds are esters, such as methyl, ethyl, phenyl, N,N-dimethylaminoethyl, acyl derivatives such as benzoyl, p-N,N-dimethylaminobenzoyl, N,N-dimethylaminoglycyl, peptide derivatives such

15 as γ -glutamyl, glycyl, D-Val-Leu-Lys.

In one embodiment, said compounds of the present invention acts as a prodrug.

The compositions containing the active compounds or pro-drugs of the present

20 invention can be formulated so as to be specifically targeted to tumours. The compounds can be attached to the reagent that is capable of binding a tumour-associated antigen. For example, the compounds of the present invention could be covalently attached to a monoclonal antibody such as directed to a tumour-associated antigen. The antigen may be located on a tumour or in the tumour cell

25 area. Such linkages can be made through peptide bond formation with amino groups of an antibody. Suitable reagents include polyclonal and monoclonal antibodies. Accordingly, the present invention also provides a method comprising treating cancer (i.e. inhibiting tumour cell growth) by administering a pharmaceutical composition comprising at least one of the compounds of the

30 present invention and a reagent (i.e. monoclonal or polyclonal antibody) which is capable of binding to a tumour associated antigen.

- 33 -

Alternatively, the compounds of the present invention could be attached to or incorporated into liposomes or carbohydrate vehicles, which are known to be useful for targeting anti-cancer drugs. Preferably the liposomes or carbohydrate vehicles can be specifically targeted to tumours by covalently attaching a monoclonal
5 antibody directed to a tumour-associated antigen.

The invention further provides a composition for treating a cancer selected from the group consisting of small cell lung cancer, testicular cancer, lymphoma, leukaemia, oesophageal cancer, stomach cancer, colon cancer, breast cancer, central nervous system cancer, liver cancer and prostate cancer, which comprising administering to
10 a mammal in need thereof an effective amount of a composition containing as an active ingredient therein at least one of the compounds of the present invention, their derivatives, metabolites, analogues and/or mimic molecules with pharmaceutical acceptable additives, diluents, carriers, excipients and pharmaceutical salts thereof.

15

The invention provides a method for inducing cellular differentiation, which comprises contacting a cancerous cell with an effective amount of at least one compound of the present invention or a derivative, metabolite, analogue or mimic molecule and pharmaceutically acceptable salts thereof.

20

The invention provides pharmaceutical formulations which consist of compositions comprising, at least one compound of the present invention and corresponding pharmaceutically acceptable derivatives, metabolites, analogues, mimic molecules and mixtures thereof are to be used as anti-neoplastic and/or anti-cancer agents.

25

The invention provides pharmaceutical formulations to be used in the preparation of medicaments having anti-neoplastic and/or anti-cancer activity.

The invention further provides, the use of the pharmaceutical formulations as anti-
30 neoplastic and/or anti-cancer agents.

- 34 -

In another embodiment, the use of pharmaceutical formulations for the preparation of medicaments having anti-neoplastic and/or anti-cancer activity.

5 In another embodiment, pharmaceutical formulations are provided, for the preparation of medicaments having activity against neoplasm and/or cancer.

The present invention is exemplified in terms of in vitro and in vivo activity against various neoplastic cell lines. The test cell lines employed in the in vitro assays are well recognised and accepted as models for anti-tumour activity in animals. The
10 term animals as used herein includes, but is not limited to, mice, rats, domesticated animals such as but is not limited to, cats, dogs, and other animals but is not limited to, cattle, sheep, pigs, horses, and primates such as but not limited to, monkeys, humans and more generally mammals.

Without further elaboration, it is believed that one skilled in the art can, using the
15 preceding description, practice the present invention to its fullest extent. The following detailed examples describe how to test the various compounds of this invention and/or perform the various processes of the invention and are to be construed as merely illustrative, and not limitations of the preceding disclosure in any way whatsoever. Those skilled in the art will promptly recognize appropriate variations
20 from the procedures.

The active components with anti-neoplastic activity were extracted from resins of plants from the plant family *Burseraceae*, primarily Myrrh (*Commiphora* spp.) and Frankincense or Olibanum (*Boswellia carteri*). The components were extracted
25 from the resins using standard extraction techniques followed by chromatographic isolation. Sample components were identified using several methods including preparative HPLC, mass spectroscopy, NMR spectroscopy, and IR and UV spectroscopy.

30 Multiple components can be extracted from the resins including: incensole, incensole acetate, incensole oxide, incensole oxide acetate, isoincensole, isoincensole acetate, isoincensole oxide, octyl acetate, octanol, terpinyl acetate, bornyl acetate, trans-ver-

- 35 -

benol, verbenone, menthadien-7-ol, terpinen-4-ol, trans-pinocarveol, carvone, borneol, farnesol, farnesene, β -caryophyllene, humulene, β -cadinene, bergamotone, β -guaiane, β -ylangene, β -bourbonene, α -copaene, terpinene, myrcene, p -cymene, α - and β -phellandrene, α -thujene, cembranes, cembrane-A, isocembrane, cembranol, cembranoids, cembranoid alcohols, furanogermacrene, furanogermacrene, germacrene, elemene, cadinene, guaiane, oplopane, eudesmane, echinodol, α -santalene, α -bisabolene, furanodiene, β -santalene, β -bergamotene, β -farnesene, β -bisabolene, T-cadinol, SKB4.

It is thought that multiple components could contribute to the anti-neoplastic components of the extracts. However the most active anti-neoplastic components comprised the diterpenoids incensole, incensole acetate, incensole oxide, incensole oxide acetate, isoincensole, isoincensole acetate, isoincensole oxide, and the furanosesquiterpene furanogermacrene in highest concentrations.

Example 1

In vitro cytotoxic activity of extracts containing high concentrations of incensole, furanogermacrene and incensole/furanogermacrene mixture were determined in several cultured tumour cell lines by performing the MTT clonogenic assay. This assay assesses the inhibition of colony formation of tumour stem cells growing in soft agar by cytotoxic agents. Since tumour stem cells are responsible for the proliferate potential and aggressiveness of a tumour cell population, the clonogenic assay is highly predictive of in vivo response.

Drugs and chemicals

The extracts were dissolved in DMSO/water 1:1, prepared as a 30 mg/ml solution and stored at -20°C until use. Final dilutions of all drugs were prepared in culture medium immediately prior to use. 5-Fluorouracil was used as a positive control and purchased from Lederle (Hamburg).

CLONOGENIC ASSAY

Single cell suspension from tumour cell lines

Human tumour cell lines were grown in RPMI 1640 supplemented with 10% fetal

- 36 -

calf serum and 2 mM L-glutamine. The cells were kept at 5% CO₂ and 37°C and passaged routinely. For treatment experiments, exponentially growing cells were trypsinized, washed twice with PBS and the percentage of viable cells was determined by hemocytometer count using trypan blue viable dye exclusion.

5

Culture methods

The clonogenic assay was performed according to a modified two-layered soft agar assay. The bottom layer consisted of 0.2 mls of Iscove's Modified Dulbecco's Medium with 20% fetal calf serum and 0.75% agar. 2.5 X 10⁴ cells in RPMI/10% FCS were added in 0.2 ml medium, but containing 0.4% agar and placed in 24-multiwell plates on top of the base layer. After 24 hours, drugs were added in additional 0.2 ml of RPMI medium. Every plate contained 6 vehicle controls and 6 different drug concentrations in triplicate. 5-fluorouracil was used as a positive control in concentrations of 100, 300 and 1000 µg/ml. Cultures were incubated at 5% CO₂ and 37°C in a humidified atmosphere for 5 – 6 days under continuous exposure to drugs and monitored closely for colony growth using an inverted microscope. Within this period, *in vitro* tumour growth led to the formation of colonies with a diameter of 50 µm. At the time of colony formation, counts were performed with automated image analysis system (OMNICOM FAS IV, Biosys GmbH). Vital colonies were stained with a sterile aqueous solution of 2-(4-iodophenyl)-3-(4-nitrophenyl)-5-phenyltetrazolium chloride (1 mg/ml, 100 µl/well) 24 hours prior to evaluation. Drug effect was assessed in terms of percentage of survival obtained by comparison to the mean number of colonies in the treated wells with mean colony count of the untreated controls: treated controls X 100 (%T/C):

25

A compound was considered active if it reduces the colony formation to 30% or less of the control group value (T/C 30%). IC₅₀ and IC₇₀ values, representing the drug concentration to inhibit colony formation by 50% (T/C 50%) and 70% (T/C 30%) respectively, were determined by plotting compound concentration versus T/C values. Mean IC₅₀ and IC₇₀ values were calculated according to the following formula:

30

n

- 37 -

$$3 \log (IC_{70})x$$

$$X=1$$

 N

5 Mean $IC_{70} = 10$

x = specific tumour cell line

n = total number of cell lines studied

If an IC_{50} or IC_{70} value could not be determined within the examined dose range, the lowest or highest concentration studies was used for the calculation. An assay was

10 considered valuable if the following criteria were fulfilled:

1. Mean number of colonies in the control group dishes for 24-multiwells contained 20 colonies with colony diameters $> 50 \mu m$.
2. The positive reference 5-flourouracil (at toxic dose of $1000 \mu g/ml$) must affect colony survival of 30% of controls.

15 Coefficient of variation in the control group $< 50\%$

The extracts were tested in several tumour cell lines, for their ability to affect tumour growth. The cell lines tested included: *HT29* colon carcinoma; *SF 268* central nervous system; *GXF 251L* gastric cancer; *LXFE 66NL* epidermoid lung carcinoma; *LXFL 529L* large cell lung carcinoma; *H460* lung adenocarcinoma; *LXFF6 529L* lung adenocarcinoma; *MCF-7* breast cancer; *OVCAR3* ovarian carcinoma; *PC3* prostate carcinoma; *DU145* prostate carcinoma; *RXF 944L* renal cell carcinoma; *MEXF 514L* melanoma; and *MEXF 426NL* melanoma.

25 The IC_{50} results are for in vitro studies are presented in Table 1 below:

Cancer Cell Line	Code Cancer Cell Line	$IC_{50} \mu m/ml$ Incensole	$IC_{50} \mu m/ml$ Furanogermacren	$IC_{50} \mu m/ml$ Incensole/ Furanogermacre n Mixture	$IC_{50} \mu m/ml$ 5- Flourouracil
Human Prostate Carcinoma	DU145	ND	ND	5.00	0.021
Human Prostate Carcinoma	PC3	6.00	70.00	1.2	ND
Human Colon Carcinoma	HT29	70.00	70.00	0.9	ND
Human Melanoma	MEXF 514L	ND	ND	0.8	ND
Human Melanoma	MEXF 429NL	ND	ND	20.00	ND

- 38 -

Human Lung Epidermoid Carcinoma	LXFE 66NL	ND	ND	50.00	ND
Human Lung Large Cell Carcinoma	LXFL 529L	ND	ND	4.00	ND
Human Lung Adenocarcinoma	H460	ND	ND	20.00	ND
Human Renal Carcinoma	RXF 944L	ND	ND	30.00	ND
Human Breast Carcinoma	MACL MCF7	ND	ND	7.00	ND
Gastric Carcinoma	GXF 251L	ND	ND	8.00	ND
Ovarian Cancer Xenograft	OVCL OVCAR3	ND	ND	10.00	ND
Carcinoma of the central nervous system	CNCL SF268	ND	ND	10.00	ND

ND = not determined

Example 2**Antimicrobial activity**

- 5 These studies were performed to determine the minimum inhibitory concentration (MIC) of incensole/furanogermacren mixture.

MIC values were determined using a macrodilution broth procedure based on NCCLS Documents M7-A3 "Methods for dilution anti-microbial susceptibility tests
10 for bacteria that grow aerobically-third edition, approved standard (1993). The lowest test substance concentration that completely inhibited growth of the test organisms recorded as MIC.

The following organisms were tested:

- 15 1. Staphylococcus aureus NCTC 10442
2. Staphylococcus aureus NCTC 6571
3. Enterococcus faecalis NCTC 775

MIC values for incensole/furanogermacren mixture were 100 µg/ml. MIC values for
20 incensole for the above 3 bacterial species was 38 µg/ml causing significant growth retardation.

Pharmaceutically acceptable refers to those properties and/or substances, which are acceptable to the patient from a pharmacological/toxicological point of view
25 including bioavailability and patient acceptance or to the manufacturing chemist.

- 39 -

from a physical-chemical point of view regarding composition, formulation, stability and isolatability.

5 The terms "comprise, comprised and comprising" and the terms "include, included and including" are used interchangeably in this specification and are to be afforded the widest interpretation.

The invention is not limited to the embodiments described above, but may be varied in both construction and detail within the scope of the claims.


WE CLAIM

5


1. A composition comprising one or more compound of the present invention, their derivatives, metabolites, analogues and/or mimic molecules with pharmaceutical acceptable additives, diluents, carriers, excipients and pharmaceutical salts thereof.

10

2. The composition as claimed in claim 1, wherein the compounds of the present invention are selected from the group comprising:



Formula (1)



Formula (2)

15

wherein for Formula (1)

Bonds between carbons 9-10, 10-1, 1-2, 2-3,3-4, 4-5, 5-6, can be either single or double with the proviso that any two or more double bonds are separated by a single bond.

20

Compounds also include those containing epoxide rings formed between carbons 9-10, 10-1, 1-2, 2-3,3-4, 4-5 with the proviso that any two or more epoxide rings are separated by a single bond.

25

wherein for Formula (2)

the carbocyclic ring can have optionally up to 7 endocyclic/exocyclic double bonds with the proviso that any two or more double bonds are separated by single bonds;

- 41 -

Carbon atoms for Formula (1) or (2) can be singly or multiply substituted, optionally and independently by:

5 an oxo substituent, H, alkyl, aryl, a heterocyclic radical, halogen, alkoxycarbonyl (C1-C5) or carboxyl, hydroxyl, alkoxy (C1-C5), amido, alkyl amido (C1-C5), amino, mono and dialkyl amino (C1-C5), alkyl carbamoyl (C1-C5), thiol, alkylthio (C1-C5);

10 in addition substituents may form a spiro ring around the carbon atom to which they are attached or they can form fused or bridged rings to adjacent carbon atoms which may be saturated or unsaturated;

15 Substituents on the aryl or heterocyclic radical are selected from the group consisting essentially of: halogen, alkyl (C1-C5), hydroxyl, alkoxy (C1-C5), alkoxycarbonyl, (C1-C5), carboxyl, amido, alkyl amido (C1-C5), amino, mono and dialkyl amino (C1-C5), alkyl carbamoyl (C1-C5), thiol, alkyl thio (C1-C5) or benzenoid aryl thio, cyano, nitro, haloalkyl (C1-C5), alkylsulfonyl (C1-C5), and sulfonate;

20 Two of such substituents can be part of a fused ring, which can be either saturated, or unsaturated, heterocyclic or carbo cyclic;

25 and natural amino acid substituents which may be attached to the compounds of formula (1) or (2) via an ester linkage to a hydroxyl group;

30 their derivatives, metabolites, analogues and/or mimic molecules with pharmaceutical acceptable additives, diluents, carriers and excipients and pharmaceutically acceptable salts thereof.

3. The composition as claimed in claims 1 or 2, wherein the compounds of the present invention are selected from the group comprising: incensole, incensole acetate, incensole oxide, incensole oxide acetate, isoincensole, isoincensole

- 42 -

acetate, isoincense oxide, octyl acetate, octanol, terpinyl acetate, bornyl acetate, trans-ver-benol, verbenone, menthadien-7-ol, terpinen-4-ol, trans-pinocarveol, carvone, borneol, farnesol, farnesene, β -caryophyllene, humulene, β -cadinene, bergamotone, β -guaiene, β -ylangene, β -bourbonene, α -copaene, terpinene, myrcene, p -cymene, α - and β -phellandrene, α -thujene, cembrane-A, isocembrane, cembranol, cembranoids, cembranoid alcohols, furanogermacrene, furanogermacrene, germacrene, elemene, cadinene, guaiane, oplopane, eudsmene, echinodol, α -santalene, α -bisabolene, furanodiene, β -santalene, β -bergamotene, β -farnesene, β -bisabolene, SKB4, their derivatives, metabolites, analogues and/or mimic molecules with pharmaceutical acceptable additives, diluents, carriers and excipients and pharmaceutically acceptable salts thereof.

4. The composition as claimed in any preceding claims, wherein the compounds of the present invention are selected from the group comprising at least one of: incense, incense acetate, incense oxide, incense oxide acetate, isoincense, isoincense acetate, isoincense oxide, and/or at least one of the furanosesquiterpene furanogermacrene, their derivatives, metabolites, analogues and/or mimic molecules with pharmaceutical acceptable additives, diluents, carriers and excipients and pharmaceutically acceptable salts thereof.

5. A pharmaceutical formulation comprising a composition as claimed in any of claims 1 to 4 and a pharmaceutically acceptable carrier thereof.

6. The pharmaceutical formulation as claimed in claim 5, wherein the pharmaceutical carrier is selected from the group comprising cyclodextrin, α -cyclodextrin, β -cyclodextrin, (β -hydroxypropylcyclodextrin) γ -cyclodextrin and vitamin E oil.

7. The use of a pharmaceutical formulation for the manufacture of a medicament for treatment of a mammal suffering from a neoplasia comprising a pharmaceutical formulation as claimed in claims 1 to 6.

8. The use of a pharmaceutical formulation as claimed in any of the preceding

- 43 -

claims, wherein the pharmaceutical formulation further includes at least one conventional chemotherapeutic agent.

9. The use of a pharmaceutical formulation as claimed in claim 7, wherein the
 5 chemotherapeutic agent is selected from the group comprising flutamide and
 luprolide, antioestrogens, such as tamoxifen, antimetabolites and cytotoxic
 agents, such as daunorubicin, fluorouracil, floxuridine, interferon alpha,
 methotrexate, plicamycin, mecaptopurine, thioguanine, adramycin, carmustine,
 lomustine, cytarabine, cyclophosphamide, doxorubicin, estramustine,
 10 altretamine, hydroxyurea, ifosfamide, procarbazine, mutamycin, busulfan,
 mitoxantrone, carboplatin, cisplatin, streptozocin, bleomycin, dactinomycin and
 idamycin, hormones such as, medroxyprogesterone, estramustine, ethinyl
 oestradiol, oestradiol, leuprolide, megestrol, octreotide, diethylstilbestrol,
 chlorotrianisene, etoposide, podophyllotoxin, and goserelin, nitrogen mustard
 15 derivatives such as, melphalan, chlorambucil, methlorethamine and thiotepa,
 steroids such as, betamethasone, and other antineoplastic agents such as live
Mycobacterium bovis, dicarbazine, asparaginase, leucovorin, mitotane,
 vincristine, vinblastine and texotere, cyclophosphamide, adriamycin, 5-
 fluorouracil, hexamethylmelamine, Acivicin; Aclarubicin; Acodazole
 20 Hydrochloride; AcrQnine; Adozelesin; Aldesleukin; Altretamine; Ambomycin;
 Ametantrone Acetate; Aminoglutethimide; Amsacrine; Anastrozole;
 Anthramycin; Asparaginase; Asperlin; Azacitidine; Azetepa; Azotomycin;
 Batimastat; Benzodepa; Bicalutamide; Bisantrene Hydrochloride; Bisnafide
 Dimesylate; Bizelesin; Bleomycin Sulfate; Brequinar Sodium; Bropiramine;
 25 Busulfan; Cactinomycin; Calusterone; Caracemide; Carbetimer; Carboplatin;
 Carmustine; Carubicin Hydrochloride; Carzelesin; Cedefingol; Chlorambucil;
 Cirolemycin; Cisplatin; Cladribine; Crisnatol Mesylate; Cyclophosphamide;
 Cytarabine; Dacarbazine; Dactinomycin; Daunorubicin Hydrochloride;
 Decitabine; Dexormaplatin; Dezaguanine; Dezaguanine Mesylate; Diaziquone;
 30 Docetaxel; Doxorubicin; Doxorubicin Hydrochloride; Droloxifene; Droloxif ne
 Citrate; Dromostanolone Propionate; Duazomycin; Edatrexate; Eflomithine
 Hydrochloride; Elsamitucin; Enloplatin; Enpromate; Epiropidine; Epirubicin
 Hydrochloride; Erbulozole; Esorubicin Hydrochloride; Estramustine;

- 44 -

Estramustine Phosphate Sodium; Etanidazole; Ethiodized Oil I 131; Etoposide;
 Etoposide Phosphate; Etoprine; Fadrozole Hydrochloride; Fazarabine;
 Fenretinide; Floxuridine; Fludarabine Phosphate; Fluorouracil; Flurocitabine;
 Fosquidone; Fostriecin Sodium; Gemcitabine; Gemcitabine Hydrochloride; Gold
 5 Au 198; Hydroxyurea; Idarubicin Hydrochloride; Ifosfamide; Ilmofofosine;
 Interferon Alfa-2a; Interferon Alfa-2b; Interferon Alfa-n1; Interferon Alfa-n3;
 Interferon Beta- I a; Interferon Gamma- I b; Iproplatin; Irinotecan Hydrochloride;
 Lanreotide Acetate; Letrozole; Leuprolide Acetate; Liarozole Hydrochloride;
 Lometrexol Sodium; Lomustine; Losoxantrone Hydrochloride; Masoprocol;
 10 Maytansine; Mechlorethamine Hydrochloride; Megestrol Acetate; Melengestrol
 Acetate; Melphalan; Menogaril; Mercaptopurine; Methotrexate; Methotrexate
 Sodium; Metoprine; Meturedapa; Mitindomide; Mitocarcin; Mitocromin;
 Mitogillin; Mitomalcin; Mitomycin; Mitosper; Mitotane; Mitoxantrone
 Hydrochloride; Mycophenolic Acid; Nocodazole; Nogalamycin; Ormaplatin;
 15 Oxisuran; Paclitaxel; Pegaspargase; Peliomycin; Pentamustine; Peplomycin
 Sulfate; Perfosfamide; Pipobroman; Pipsulfan; Piroxantrone Hydrochloride;
 Plicamycin; Plomestane; Porfimer Sodium; Porfiromycin; Prednimustine;
 Procarbazine Hydrochloride; Puromycin; Puromycin Hydrochloride; Pyrazofurin;
 Riboprine; Rogletimide; Safmgol; Safingol Hydrochloride; Semustine;
 20 Simtrazene; Sparfosate Sodium; Sparsomycin; Spirogermanium Hydrochloride;
 Spiromustine; Spiroplatin; Streptonigrin; Streptozocin; Strontium Chloride Sr 89;
 Sulofenur; Talisomycin; Taxane; Taxoid; Tecogalan Sodium; Tegafur;
 Teloxantrone Hydrochloride; Temoporfin; Tenipōside; Teroxirone; Testolactone;
 Thiamiprine; Thioguanine; Thiotepa; Tiazofurin; Tirapazamine; Topotecan
 25 Hydrochloride; Toremifene Citrate; Trestolone Acetate; Triciribine Phosphate;
 Trimetrexate; Trimetrexate Glucuronate; Triptorelin; Tubulozole Hydrochloride;
 Uracil Mustard; Uredapa; Vapreotide; Verteporfin; Vinblastine Sulfate;
 Vincristine Sulfate; Vindesine; Vindesine Sulfate; Vinepidine Sulfate;
 Vinglycinat Sulfate; Vinleurosine Sulfate; Vinorelbine Tartrate; Vinrosidine
 30 Sulfate; Vinzolidine Sulfate; Vorozole; Zeniplatin; Zinostatin; Zorubicin
 Hydrochloride, 20-epi-1,25 dihydroxyvitamin D3; 5-ethynyluracil; abiraterone;
 aclarubicin; acylfulvene; adecyphenol; adozelesin; aldesleukin; ALL-TK
 antagonists; altretamine; ambamustine; amidox; amifostine; aminolevulinic acid;

- 45 -

amrubicin; atrsacrine; anagrelide; anastrozole; andrographolide; angiogenesis
 inhibitors; antagonist D; antagonist G; DHEA; bromineepiandrosterone;
 epiandrosterone; antarelix; anti-dorsalizing morphogenetic protein-1;
 antiandrogen, prostatic carcinoma; antiestrogen; antineoplaston; antisense
 5 oligonucleotides; aphidicolin glycinate; apoptosis gene modulators; apoptosis
 regulators; apurinic acid; ara-CDP-DL-PTBA; arginine deaminase; asulacrine;
 atamestane; atrimustine; axinastatin 1; axinastatin 2; axinastatin 3; azasetron;
 azatoxin; azatyrosine; baccatin III derivatives; balanol; batimastat; BCR/ABL
 antagonists; benzochlorins; benzoylstaurosporine; beta lactam derivatives;
 10 beta-alethine; betaclamycin B; betulinic acid; bFGF inhibitor; bicalutamide;
 bisantrene; bisaziridinylspermine; bisnafide; bistratene A; bizelesin; breflate;
 bropiramine; budotitane; buthionine sulfoximine; calcipotriol; calphostin C;
 camptothecin derivatives; canarypox IL-2; capecitabine; carboxamide-amino-
 triazole; carboxyamidotriazole; CaRest M3; CARN 700; cartilage derived
 15 inhibitor; carzelesin; casein kinase inhibitors (ICOS); castanospermine; cecropin
 B; cetorelix; chlorins; chloroquinoxaline sulfonamide; cicaprost; cis-porphyrin;
 cladribine; clomifene analogues; clotrimazole; collismycin A; collismycin B;
 combretastatin A4; combretastatin analogue; conagenin; crambescidin 816;
 crisnatol; cryptophycin 8; cryptophycin A derivatives; curacin A;
 20 cyclopentantraquinones; cycloplatam; cypemycin; cytarabine ocfosfate;
 cytolytic factor; cytostatin; dacliximab; decitabine; dehydrididemnin B;
 deslorelin; dexifosfamide; dexrazoxane; dexverapamil; diaziqune; didemnin B;
 didox; diethylnorspermine; dihydro-5-azacytidine; dihydrotaxol, 9-; dioxamycin;
 diphenyl spiromustine; docosanol; dolasetron; doxifluridine; droloxifene;
 25 dronabinol; duocannycin SA; ebselen; ecomustine; edelfosine; edrecolomab;
 eflornithine; elemene; emitefur; epirubicin; epristeride; estramustine analogue;
 estrogen agonists; estrogen antagonists; etanidazole; etoposide phosphate;
 exemestane; fadrozole; fazarabine; fenretinide; filgrastim; fmasteride;
 flavopiridol; flezelastine; fluasterone; fludarabine; fluorodaunorunicin
 30 hydrochloride; forfenimex; formestane; fostriecin; fotemustine; gadolinium
 texaphyrin; gallium nitrate; galocitabine; ganirelix; gelatinase inhibitors;
 gemcitabine; glutathione inhibitors; hepsulfam; heregulin; hexamethylene
 bisacetamide; hypericin; ibandronic acid; idarubicin; idoxifene; idramantone;

- 46 -

ilmofosine; ilomastat; imidazoacridones; imiquimod; immunostimulant peptides;
 insulin-like growth factor-1 receptor inhibitor; interferon agonists; interferons;
 interleukins; iobenguane; iododoxorubicin; ipomeanol, 4-; irinotecan; iroplact;
 irsogladine; isobengazole; isohomohalicondrin B; itasetron; jasplakinolide;
 5 kahalalide F; lamellarin-N triacetate; lanreotide; leinamycin; lenograstim;
 lentinan sulfate; leptolstatin; letrozole; leukemia inhibiting factor; leukocyte
 alpha interferon; leuprolide+estrogen+progesterone; leuprorelin; levamisole;
 liarozole; linear polyamine analogue; lipophilic disaccharide peptide; lipophilic
 platinum compounds; lissoclinamide 7; lobaplatin; lombricine; lometrexol;
 10 lonidamine; losoxantrone; lovastatin; loxoribine; lurtotecan; lutetium texaphyrin;
 lysofylline; lytic peptides; maitansine; mannostatin A; marimastat; masoprocol;
 maspin; matrilysin inhibitors; matrix metalloproteinase inhibitors; menogaril;
 merbarone; meterelin; methioninase; metoclopramide; MIF inhibitor;
 mifepristone; miltefosine; mirimostim; mismatched double stranded RNA;
 15 mitoguazone; mitolactol; mitomycin analogues; mitonafide; mitotoxin fibroblast
 growth factor-saporin; mitoxantrone; mofarotene; molgramostim; monoclonal
 antibody, human chorionic gonadotrophin; monophosphoryl lipid A
 +myobacterium cell wall sk; mopidamol; multiple drug resistance genie inhibitor;
 multiple tumor suppressor 1-based therapy; mustard anticancer agent;
 20 mycaperoxide B; mycobacterial cell wall extract; myriaporone; N-acetyldinaline;
 N-substituted benzamides; nafarelin; nagrestip; naloxone +pentazocine;
 napavin; naphterpin; nartograstim; nedaplatin; nemorubicin; neridronic acid;
 neutral endopeptidase; nilutamide; nisamycin; nitric oxide modulators; nitroxide
 antioxidant; nitrullyn; O6-benzylguanine; octreotide; okicenone;
 25 oligonucleotides; onapristone; ondansetron; ondansetron; oracin; oral cytokine
 inducer; ormaplatin; osaterone; oxaliplatin; oxaunomycin; paclitaxel analogues;
 paclitaxel derivatives; palauamine; palmitoylrhizoxin; pamidronic acid;
 panaxytriol; panomifene; parabactin; pazelliptine; pegaspargase; peldesine;
 pentosan polysulfate sodium; pentostatin; pentozole; perflubron; perfosfamide;
 30 perillyl alcohol; phenazinomycin; phenylacetate; phosphatase inhibitors;
 picibanil; pilocarpine hydrochloride; pirarubicin; piritrexim; placetin A; placetin B;
 plasminogen activator inhibitor; platinum complex; platinum compounds;
 platinum-triamine complex; porfimer sodium; porfiromycin; propyl bis-acridone;

- 47 -

prostaglandin J2; proteasome inhibitors; protein A-based immune modulator;
 protein kinase C inhibitor; protein kinase C inhibitors, microalgal; protein
 tyrosine phosphatase inhibitors; purine nucleoside phosphorylase inhibitors;
 purpurins; pyrazoloacridine; pyridoxylated hemoglobin polyoxyethylene
 5 conjugate; raf antagonists; raltitrexed; ramosetron; ras farnesyl protein
 transferase inhibitors; ras inhibitors; ras-GAP inhibitor; retelliptine
 demethylated; rhenium Re 186 etidronate; rhizoxin; ribozymes; RII retinamide;
 rogletimide; rohitukine; romurtide; roquinimex; rubiginone B1; ruboxyl; safingol;
 saintopin; SarCNU; sarcophytol A; sargramostim; Sdi 1 mimetics; semustine;
 10 senescence derived inhibitor 1; sense oligonucleotides; signal transduction
 inhibitors; signal transduction modulators; single chain antigen binding protein;
 sizofiran; sobuzoxane; sodium borocaptate; sodium phenylacetate; solverol;
 somatomedin binding protein; sonermin; sparfosic acid; spicamycin D;
 spiromustine; splenopentin; spongistatin 1; squalamine; stem cell inhibitor;
 15 stem-cell division inhibitors; stipiamide; stromelysin inhibitors; sulfmosine;
 superactive vasoactive intestinal peptide antagonist; suradista; suramin;
 swainsonine; synthetic glycosaminoglycans; tallimustine; tamoxifen methiodide;
 tauromustine; tazarotene; tecogalan sodium; tegafur; tellurapyrylium;
 telomerase inhibitors; temoporfin; temozolomide; teniposide;
 20 tetrachlorodecaoxide; tetrazomine; thaliblastine; thalidomide; thiocoraline;
 thrombopoietin; thrombopoietin mimetic; thymalfasin; thymopoietin receptor
 agonist; thymotrnan; thyroid stimulating hormone; tin ethyl etiopurpurin;
 tirapazamine; titanocene dichloride; topotecan; Topsentin; toremifene; totipotent
 stem cell factor; translation inhibitors; tretinoin; triacetyluridine; tricinibine;
 25 trimetrexate; triptorelin; tropisetron; turosteride; tyrosine kinase inhibitors;
 tyrphostins; UBC inhibitors; ubenimex; urogenital sinus-derived growth
 inhibitory factor; urokinase receptor antagonists; vaporeotide; variolin B; vector
 system, erythrocyte gene therapy; velaresol; venom, anti-venom, veramine;
 verdins; verteporfin; vinorelbine; vinxaltine; vitaxin; vorozole; zanoterone;
 30 zeniplatin; zilascorb; zinostatin stimalamer, immunostimulating drugs or
 therapeutic agents, their metabolites, salts and derivatives thereof.

- 48 -

10. The use of a pharmaceutical formulation as claimed in claims 7 to 9, wherein the pharmaceutical formulation is administered in combination with radiation treatment.
- 5 11. The use of a pharmaceutical formulation as claimed in claims 7 to 10, wherein the pharmaceutical formulation is administered in combination with surgery.
12. The use of a pharmaceutical formulation as claimed in claims 7 to 11, wherein the neoplasia is a precancerous lesion including syndromes represented by
10 abnormal neoplastic and/or dysplastic, changes of tissue comprising precancerous growths in colonic, breast, renal, central nervous, gastric, or lung tissues, or conditions such as dysplastic nevus syndrome, a precursor to malignant melanoma of the skin, dysplastic nevus syndromes, polyposis syndromes, colonic polyps, precancerous lesions of the cervix (i.e., cervical
15 dysplasia), prostatic dysplasia, bronchial dysplasia, breast, bladder and/or skin and related conditions (e.g., actinic keratosis), whether the lesions are clinically identifiable or not.
13. The use of a pharmaceutical formulation as claimed in claims 7 to 12, wherein the neoplasia is prostate cancer, colon cancer, small cell lung cancer, large cell
20 lung cancer, lung adenocarcinoma, epidermoid lung cancer, melanoma (including amelanotic subtypes), renal cell carcinoma, gastric carcinoma, cancers of the central nervous system including brain tumours, neuroblastomas, gastric carcinoma, breast cancer, ovarian cancer, testicular cancer, lymphoma and leukaemia, oesophageal cancer, stomach cancer, liver
25 cancers, prostate cancer, cervical cancer, adrenal cancer, oral or mucosal cancer, bladder cancer, pancreatic cancer, lymphoma, Hodgkins disease, sarcomas. Hematopoietic cell cancers such as B cell leukaemia/lymphomas, myelomas, T-cell leukemias/lymphomas, small cell leukemias/lymphomas, null cell, sezary, monocytic, myelomonocytic and Hairy cell leukemias.
- 30 14. The use of a pharmaceutical formulation as claimed in claims 7 to 13, wherein the neoplasia is in the form of a tumour comprising an epidermoid and myeloid tumour, acute or chronic, non-small cell, squamous or solid.

- 49 -

15. The use of a pharmaceutical formulation as claimed in claims 7 to 14, wherein the composition is micronized.
- 5 16. The use of a pharmaceutical formulation as claimed in claims 7 to 15, wherein the pharmaceutical formulation has an enteric coating.
17. The use of a pharmaceutical formulation as claimed in claim 16, wherein the enteric coating is made of a polymer or copolymer.
- 10 18. The use of a pharmaceutical formulation as claimed in claim 17, wherein the polymer or copolymer is selected from the group consisting of poly(lactic-glycolic acid) polyester, cellulose acetate phthalate, hydroxypropyl-methyl cellulose phthalate poly(butyl methacrylate), (2-dimethyl aminoethyl) methacrylate, and methyl methacrylate.
- 15 19. The use of a pharmaceutical formulation as claimed in claims 7 to 18, wherein, the pharmaceutical formulation is administered enterally, parenterally, topically, orally, sub-lingually, rectally, nasally or vaginally.
- 20 20. The use of a pharmaceutical formulation as claimed in claims 7 to 19, where in the composition is formulated into liposomes or carbohydrate vehicles.
21. The use of a pharmaceutical formulation as claimed in claim 20, wherein the liposomes or carbohydrate vehicles are specifically targeted to tumours by covalently attaching a monoclonal antibody directed to a tumour-associated antigen.
- 25 22. The use of a pharmaceutical formulation as claimed in claims 7 to 21, wherein the pharmaceutical formulation is administered intermittently.
- 30 23. The use of a pharmaceutical formulation as claimed in claims 7 to 22, where in the pharmaceutical formulation is a unit dose that comprises 5-500 mg of active

- 50 -

ingredient consisting of at least one compound of the present invention.

24. The use of a pharmaceutical formulation as claimed in claims 7 to 23, wherein the pharmaceutical formulation is administered to a mammal.

5

25. The use of a pharmaceutical formulation as claimed in claim 24, wherein said mammal is a neonate and said administering is effected prior to delivery of said neonate and/or during delivery of said neonate.

10 26. The use of a pharmaceutical formulation as claimed in claims 7 to 25, wherein said compounds of the present invention acts as a prodrug.

27. The use of a pharmaceutical formulation for the manufacture of a medicament for treatment of a mammal suffering from an immunodysregulatory condition comprising a composition as claimed in claims 1 to 6, to a subject.

15

28. The use of a pharmaceutical formulation as claimed in claim 27, wherein the immunodysregulation condition is caused by a viral infection, intracellular bacterial infection, extracellular bacterial infection, fungal infection, yeast infection, extracellular parasite infection, intracellular parasite infection, protozoan parasite, multicellular parasite, autoimmune disease, immunosuppressive therapy, chemotherapy, anti-infective agent therapy, wound, burn, the presence of an immunosuppressive molecule, gastrointestinal irritation or any combination of the foregoing is selected from (a) a DNA virus infection or an RNA virus (b) a parasite infection, a *Trypanosoma*, *Plasmodium*, *Cryptosporidium*, *Entamoeba*, *Balantidium*, *Leishmania*, *Pneumocystis*, *Trichomoniasis* or *Toxoplasma* infection, wherein the *Trypanosoma*, *Plasmodium*, *Cryptosporidium*, *Entamoeba*, *Balantidium*, *Leishmania*, *Pneumocystis*, *Trichomoniasis* or *Toxoplasma* infection is selected from but not limited to *Trypanosoma cruzi*, *Trypanosoma brucei*, *Trypanosoma gambiense*, *Trypanosoma rhodesiense*, *Plasmodium falciparum*, *Plasmodium vivax*, *Plasmodium malariae*, *Plasmodium ovale*, *Plasmodium berghei*, *Entamoeba histolytica*, *Balantidium coli*, *Leishmania braziliensis*, *Leishmania mexicana*,

20

25

30

- 51 -

Leishmania donovani, *Leishmania tropica*, *Pneumocystis carinii*, *Trichomoniasis vaginalis*, and *Toxoplasma gondii* (c) a mycoplasma infection, a *Listeria* infection or a *Mycobacterium* infection; (d) a *Streptococcus* infection, a *Staphylococcus* infection, a *Vibrio* infection, a *Salmonella* infection; a *Shigella* infection, an enterotoxigenic, enteropathogenic, enteroinvasive or enterohemorrhagic *E. coli* infection, a *Yersinia* infection, a *Campylobacter* infection, a *Pseudomonas* infection, a *Borrelia* infection, a *Legionella* infection and a *Haemophilus* infection; (e) pulmonary *Aspergillosis*, mucosal or oropharyngeal candidiasis and juvenile paracoccidiomycosis; (f) a *Candida* infection and a *Cryptococcus* infection; (g) systemic lupus erythematosus, arthritis, asthma, and diabetes (h) adriamycin treatment, cisplatin treatment, mitomycin C treatment, amphotericin B treatment; (i) a gamma-radiation treatment; (j) nucleoside analog treatment for viral infection or for cancer; (k) surgical and accidental wounds, septic shock caused by surgery; (l) cyclosporin treatment and corticosteroid treatment; (m) irritable bowel treatment, Crohn's disease, wasting syndrome, cachexia, Motor Neuron disease, Multiple Sclerosis, inflammatory bowel disease, respiratory distress syndrome, chronic diarrhoea; (n) cancer; (o) cirrhosis; (p) gram positive multi-drug resistant bacteria or (q) any combination of (a) through (p).

20

29. The use of a pharmaceutical formulation as claimed in claim 28, wherein the DNA virus infection or the RNA virus infection is selected from a retrovirus infection, a togavirus infection, a flavivirus infection, a rubivirus infection, a pestivirus infection, a lipid envelope virus infection, a filovirus, a picornavirus infection, a rhinovirus infection, a coronavirus infection, a respiratory syncytial virus infection, a poliovirus infection, a parainfluenza virus infection, influenza virus infection, hantavirus, adeno-associated virus, measles virus, poxvirus, filovirus, human papilloma virus and animal papilloma virus infection.

25

30. The use of a pharmaceutical formulation as claimed in claims 27 to 29, wherein the composition further includes at least one conventional chemotherapeutic agent.

30

- 52 -

31. The pharmaceutical formulation as claimed in claim 30, wherein the chemotherapeutic agent is selected from the group comprising flutamide and luprolide, antioestrogens, such as tamoxifen, antimetabolites and cytotoxic agents, such as daunorubicin, fluorouracil, floxuridine, interferon alpha, methotrexate, plicamycin, mercaptopurine, thioguanine, adramycin, carmustine, lomustine, cytarabine, cyclophosphamide, doxorubicin, estramustine, altretamine, hydroxyurea, ifosfamide, procarbazine, mutamycin, busulfan, mitoxantrone, carboplatin, cisplatin, streptozocin, bleomycin, dactinomycin and idamycin, hormones such as, medroxyprogesterone, estramustine, ethinyl oestradiol, oestradiol, leuprolide, megestrol, octreotide, diethylstilbestrol, chlorotrianisene, etoposide, podophyllotoxin, and goserelin, nitrogen mustard derivatives such as, melphalan, chlorambucil, methlorethamine and thiotepa, steroids such as, betamethasone, and other antineoplastic agents such as live *Mycobacterium bovis*, dicarbazine, asparaginase, leucovorin, mitotane, vincristine, vinblastine and taxotere, cyclophosphamide, adriamycin, 5-fluorouracil, hexamethylmelamine, Acivicin; Aclarubicin; Acodazole Hydrochloride; AcrQnine; Adozelesin; Aldesleukin; Altretamine; Ambomycin; Ametantrone Acetate; Aminoglutethimide; Amsacrine; Anastrozole; Anthramycin; Asparaginase; Asperlin; Azacitidine; Azetepa; Azotomycin; Batimastat; Benzodepa; Bicalutamide; Bisantrone Hydrochloride; Bisnafide Dimesylate; Bizelesin; Bleomycin Sulfate; Brequinar Sodium; Bropirimine; Busulfan; Cactinomycin; Calusterone; Caracemide; Carbetimer; Carboplatin; Carmustine; Carubicin Hydrochloride; Carzelesin; Cedefingol; Chlorambucil; Cirolemycin; Cisplatin; Cladribine; Crisnatol Mesylate; Cyclophosphamide; Cytarabine; Dacarbazine; Dactinomycin; Daunorubicin Hydrochloride; Decitabine; Dexormaplatin; Dezaguanine; Dezaguanine Mesylate; Diaziquone; Docetaxel; Doxorubicin; Doxorubicin Hydrochloride; Droloxifene; Droloxifene Citrate; Dromostanolone Propionate; Duazomycin; Edatrexate; Eflomithine Hydrochloride; Elsamitrucin; Enloplatin; Enpromate; Epiripidine; Epirubicin Hydrochloride; Erbulozole; Esorubicin Hydrochloride; Estramustine; Estramustine Phosphate Sodium; Etanidazole; Ethiodized Oil I 131; Etoposide; Etoposide Phosphate; Etoprine; Fadrozole Hydrochloride; Fazarabine; Fenretinide; Floxuridine; Fludarabine Phosphate; Fluorouracil; Flurocitabine;

- 53 -

Fosquidone; Fostriecin Sodium; Gemcitabine; Gemcitabine Hydrochloride; Gold
 Au 198; Hydroxyurea; Idarubicin Hydrochloride; Ifosfamide; Ilmofoesine;
 Interferon Alfa-2a; Interferon Alfa-2b; Interferon Alfa-n1; Interferon Alfa-n3;
 Interferon Beta- 1 a; Interferon Gamma- 1 b; Iproplatin; Irinotecan Hydrochlorid ;
 5 Lanreotide Acetate; Letrozole; Leuprolide Acetate; Liarozole Hydrochloride;
 Lometrexol Sodium; Lomustine; Losoxantrone Hydrochloride; Masoprocol;
 Maytansine; Mechlorethamine Hydrochloride; Megestrol Acetate; Melengestrol
 Acetate; Melfalan; Menogaril; Mercaptopurine; Methotrexate; Methotrexate
 Sodium; Metoprine; Meturedopa; Mitindomide; Mitocarcin; Mitocromin;
 10 Mitogillin; Mitomalcin; Mitomycin; Mitosper; Mitotane; Mitoxantrone
 Hydrochloride; Mycophenolic Acid; Nocodazole; Nogalamycin; Ormaplatin;
 Oxisuran; Paclitaxel; Pegaspargase; Peliomycin; Pentamustine; Peplomycin
 Sulfate; Perfosfamide; Pipobroman; Pipo sulfan; Piroxantrone Hydrochloride;
 Plicamycin; Plomestane; Porfimer Sodium; Porfiromycin; Prednimustine;
 15 Procarbazine Hydrochloride; Puromycin; Puromycin Hydrochloride; Pyrazofurin;
 Riboprine; Rogletimide; Safmgol; Safingol Hydrochloride; Semustine;
 Simtrazene; Sparfosate Sodium; Sparsomycin; Spirogermanium Hydrochloride;
 Spiromustine; Spiroplatin; Streptonigrin; Streptozocin; Strontium Chloride Sr 89;
 Sulofenur; Talisomycin; Taxane; Taxoid; Tecogalan Sodium; Tegafur;
 20 Teloxantrone Hydrochloride; Temoporphin; Teniposide; Teroxirone; Testolactone;
 Thiamiprine; Thioguanine; Thiotepa; Tiazofurin; Tirapazamine; Topotecan
 Hydrochloride; Toremifene Citrate; Trestolone Acetate; Triciribine Phosphate;
 Trimetrexate; Trimetrexate Glucuronate; Triptorelin; Tubulozole Hydrochloride;
 Uracil Mustard; Uredopa; Vapreotide; Verteporfin; Vinblastine Sulfate;
 25 Vincristine Sulfate; Vindesine; Vindesine Sulfate; Vinepidine Sulfate;
 Vinglycinat Sulfate; Vinleurosine Sulfate; Vinorelbine Tartrate; Vinrosidine
 Sulfate; Vinzolidine Sulfate; Vorozole; Zeniplatin; Zinostatin; Zorubicin
 Hydrochloride, 20-epi-1,25 dihydroxyvitamin D3; 5-ethynyluracil; abiraterone;
 aclarubicin; acylfulvene; adecypenol; adozelesin; aldesleukin; ALL-TK
 30 antagonists; altretamine; ambamustine; amidox; amifostine; aminolevulinic acid;
 amrubicin; atrsacrine; anagrelide; anastrozole; andrographolide; angiogenesis
 inhibitors; antagonist D; antagonist G; DHEA; bromineepiandrosterone;
 epiandrosterone; antarelix; anti-dorsalizing morphogenetic protein-1;

- 54 -

antiandrogen, prostatic carcinoma; antiestrogen; antineoplaston; antisense
 oligonucleotides; aphidicolin glycinate; apoptosis gene modulators; apoptosis
 regulators; apurinic acid; ara-CDP-DL-PTBA; arginine deaminase; asulacrine;
 atamestane; atrimustine; axinastatin 1; axinastatin 2; axinastatin 3; azasetron;
 5 azatoxin; azatyrosine; baccatin III derivatives; balanol; batimastat; BCR/ABL
 antagonists; benzochlorins; benzoylstauroporine; beta lactam derivatives;
 beta-alethine; betaclamycin B; betulinic acid; bFGF inhibitor; bicalutamide;
 bisantrene; bisaziridinylspermine; bisnafide; bistratene A; bizelesin; breflate;
 broprimine; budotitane; buthionine sulfoximine; calcipotriol; calphostin C;
 10 camptothecin derivatives; canarypox IL-2; capecitabine; carboxamide-amino-
 triazole; carboxyamidotriazole; CaRest M3; CARN 700; cartilage derived
 inhibitor; carzelesin; casein kinase inhibitors (ICOS); castanospermine; cecropin
 B; cetorelix; chlorins; chloroquinoxaline sulfonamide; cicaprost; cis-porphyrin;
 cladribine; clomifene analogues; clotrimazole; collismycin A; collismycin B;
 15 combretastatin A4; combretastatin analogue; conagenin; crambescidin 816;
 crisnatol; cryptophycin 8; cryptophycin A derivatives; curacin A;
 cyclopentantraquinones; cycloplatam; cypemycin; cytarabine ocfosfate;
 cytolytic factor; cytostatin; dacliximab; decitabine; dehydrodidemnin B;
 deslorelin; dexifosfamide; dexrazoxane; dexverapamil; diaziquone; didemnin B;
 20 didox; diethylnorspermine; dihydro-5-azacytidine; dihydrotaxol, 9-; dioxamycin;
 diphenyl spiromustine; docosanol; dolasetron; doxifluridine; droloxifene;
 dronabinol; duocannycin SA; ebselen; ecomustine; edelfosine; edrecolomab;
 eflornithine; elemene; emitefur; epirubicin; epristeride; estramustine analogue;
 estrogen agonists; estrogen antagonists; etanidazole; etoposide phosphate;
 25 exemestane; fadrozole; fazarabine; fenretinide; filgrastim; fmasteride;
 flavopiridol; flezelastine; fluasterone; fludarabine; fluorodaunorubicin
 hydrochloride; forfenimex; formestane; fostriecin; fotemustine; gadolinium
 texaphyrin; gallium nitrate; galocitabine; ganirelix; gelatinase inhibitors;
 gemcitabine; glutathione inhibitors; hepsulfam; heregulin; hexamethylene
 30 bisacetamide; hypericin; ibandronic acid; idarubicin; idoxifene; idramantone;
 ilmofofosine; ilomastat; imidazoacridones; imiquimod; immunostimulant peptides;
 insulin-like growth factor-1 receptor inhibitor; interferon agonists; interferons;
 interleukins; iobenguane; iododoxorubicin; ipomeanol, 4-; irinotecan; iroplact;

- 55 -

irsogladine; isobengazole; isohomohalicondrin B; itasetron; jasplakinolide;
 kahalalide F; lamellarin-N triacetate; lanreotide; leinamycin; lenograstim;
 lentinan sulfate; leptolstatin; letrozole; leukemia inhibiting factor; leukocyte
 alpha interferon; leuprolide+estrogen+progesterone; leuprorelin; levamisole;
 5 liarozole; linear polyamine analogue; lipophilic disaccharide peptide; lipophilic
 platinum compounds; lissoclinamide 7; lobaplatin; lombricine; lometrexol;
 lonidamine; losoxantrone; lovastatin; loxoribine; lurtotecan; lutetium texaphyrin;
 lysofylline; lytic peptides; maitansine; mannostatin A; marimastat; masoprocot;
 maspin; matrilysin inhibitors; matrix metalloproteinase inhibitors; menogaril;
 10 merbarone; meterelin; methioninase; metoclopramide; MIF inhibitor;
 mifepristone; miltefosine; mirimostim; mismatched double stranded RNA;
 mitoguazone; mitolactol; mitomycin analogues; mitonafide; mitotoxin fibroblast
 growth factor-saporin; mitoxantrone; mofarotene; molgramostim; monoclonal
 antibody, human chorionic gonadotrophin; monophosphoryl lipid A
 15 +myobacterium cell wall sk; mopidamol; multiple drug resistance genie inhibitor;
 multiple tumor suppressor 1-based therapy; mustard anticancer agent;
 mycaperoxide B; mycobacterial cell wall extract; myriaporone; N-acetyldinaline;
 N-substituted benzamides; nafarelin; nagrestip; naloxone +pentazocine;
 napavin; naphterpin; nartograstim; nedaplatin; nemorubicin; neridronic acid;
 20 neutral endopeptidase; nilutamide; nisamycin; nitric oxide modulators; nitroxide
 antioxidant; nitrullyn; O6-benzylguanine; octreotide; okicenone;
 oligonucleotides; onapristone; ondansetron; ondansetron; oracin; oral cytokine
 inducer; ormaplatin; osaterone; oxaliplatin; oxaunomycin; paclitaxel analogues;
 paclitaxel derivatives; palauamine; palmitoylrhizoxin; pamidronic acid;
 25 panaxytriol; panomifene; parabactin; pazelliptine; pegaspargase; peldesine;
 pentosan polysulfate sodium; pentostatin; pentozole; perflubron; perfosfamide;
 perillyl alcohol; phenazinomycin; phenylacetate; phosphatase inhibitors;
 picibanil; pilocarpine hydrochloride; pirarubicin; piritrexim; placetin A; placetin B;
 plasminogen activator inhibitor; platinum complex; platinum compounds;
 30 platinum-triamine complex; porfimer sodium; porfiromycin; propyl bis-acridone;
 prostaglandin J2; proteasome inhibitors; protein A-based immune modulator;
 protein kinase C inhibitor; protein kinase C inhibitors, microalgal; protein
 tyrosine phosphatase inhibitors; purine nucleoside phosphorylase inhibitors;

- 56 -

- purpurins; pyrazoloacridine; pyridoxylated hemoglobin polyoxyethylene
 conjugate; raf antagonists; raltitrexed; ramosetron; ras farnesyl protein
 transferase inhibitors; ras inhibitors; ras-GAP inhibitor; retelliptine
 demethylated; rhenium Re 186 etidronate; rhizoxin; ribozymes; RII retinamide;
 5 rogletimide; rohitukine; romurtide; roquinimex; rubiginone B1; ruboxyl; safingol;
 saintopin; SarCNU; sarcophytol A; sargramostim; Sdi 1 mimetics; semustine;
 senescence derived inhibitor 1; sense oligonucleotides; signal transduction
 inhibitors; signal transduction modulators; single chain antigen binding protein;
 sizofiran; sobuzoxane; sodium borocaptate; sodium phenylacetate; solverol;
 10 somatomedin binding protein; sonermin; sparfosic acid; spicamycin D;
 spiromustine; splenopentin; spongistatin 1; squalamine; stem cell inhibitor;
 stem-cell division inhibitors; stipiamide; stromelysin inhibitors; sulfmosine;
 superactive vasoactive intestinal peptide antagonist; suradista; suramin;
 swainsonine; synthetic glycosaminoglycans; tallimustine; tamoxifen methiodide;
 15 tauromustine; tazarotene; tecogalan sodium; tegafur; tellurapyrylium;
 telomerase inhibitors; temoporfin; temozolomide; teniposide;
 tetrachlorodecaoxide; tetrazomine; thaliblastine; thalidomide; thiocoraline;
 thrombopoietin; thrombopoietin mimetic; thymalfasin; thymopoietin receptor
 agonist; thymotrigan; thyroid stimulating hormone; tin ethyl etiopurpurin;
 20 tirapazamine; titanocene dichloride; topotecan; topsentin; toremifene; totipotent
 stem cell factor; translation inhibitors; tretinoin; triacetyluridine; tricirbine;
 trimetrexate; triptorelin; tropisetron; turosteride; tyrosine kinase inhibitors;
 tyrphostins; UBC inhibitors; ubenimex; urogenital sinus-derived growth
 inhibitory factor; urokinase receptor antagonists; vapreotide; variolin B; vector
 25 system, erythrocyte gene therapy; velaresol; venom, anti-venom, veramine;
 verdins; verteporfin; vinorelbine; vinxaltine; vitaxin; vorozole; zanoterone;
 zeniplatin; zilascorb; zinostatin stimalamer, immunostimulating drugs or
 therapeutic agents, their metabolites, salts and derivatives thereof .
- 30 32. The use of a pharmaceutical formulation as claimed in claims 27 to 31, wherein
 the composition further includes at least one anti-viral agent.

33. The use of a pharmaceutical formulation as claimed in claim 32, wherein the

- 57 -

anti-viral agents are selected from the group comprising nucleoside analogues (AZT; ddC; ddI; d4T; 3TC; BW 1592; PMEA/bis-POM PMEA; dOTC; DAPD); non-nucleoside reverse transcriptase inhibitors (delavirdine; DMP 266; HBY097; loviride; nevirapine, emivirine; AG1549; PNU142721; Calanolide A; DPC961); protease inhibitors (ABT-378; ritonavir; nelfinavir; BW 141; KNI-272; indinavir; saquinavir; L-756,423; DMP-450; BMS-232630); ALX40-4C; hydroxyurea; lobucavir; pentafuside; T-1249; PRO 542; FP-21399; AMD 3100; HE-2000 and peptide T; Abacavir; Acemannan; Acyclovir; Acyclovir Sodium; Adefovir; Alovudine; Alvircept Sudotox; Amantadine Hydrochloride; Aranotin; Arildone; Ateviridine Mesylate; Avridine; Cidofovir; Cipamfylline; Coviracil; Cytarabine Hydrochloride; Delavirdine Mesylate; Desciclovir; Didanosine; Disoxaril; Edoxudine; Emivirine; Emtricitabine; Enviradene; Enviroxime; Epivir; Famciclovir; Famotidine Hydrochloride; Fiacitabine; Fialuridine; Fosarilate; Foscarnet Sodium; Fosfonet Sodium; Ganciclovir; Ganciclovir Sodium; Idoxuridine; Indinavir; Kethoxal; Lamivudine; Lobucavir; Lodenosine; Lopinavir; Memotidine Hydrochloride; Methisazone; Nelfinavir; Nevirapine; Penciclovir; Pirodavin; Ribavirin; Rimantadine Hydrochloride; Saquinavir Mesylate; Ritonavir; Somantadine Hydrochloride; Sorivudine; Statolon; Stavudine; Tenofovir; Tilorone Hydrochloride; Trifluridine; Valacyclovir Hydrochloride; Vidarabine; Vidarabine Phosphate; Vidarabine Sodium Phosphate; Tipranavir, Viroxime; Zalcitabine; Zidovudine; Zinviroxime and Interferon.

34. The use of a pharmaceutical formulation as claimed in claims 27 to 33, wherein the composition further includes at least one anti-parasite agent.

25

35. The use of a pharmaceutical formulation as claimed in claim 34, wherein the anti-parasite agents are selected from the group comprising chloroquin, primaquine, mefloquine, pyrimethamine-sulfadoxone, atoraquone/dapsone; halofantrine; artemisinin derivatives; atoraquone + proguanil, co-artemether; podophyllotoxin; pentamidine, diloxanide furoate, metronidazole, tindazole, tetracycline, quinacrine, stibogluconate, amphotericin B, quinine, doxycycline, trimethoprim-sulfamethoxazole, metronidazole, nifurtimox, suramin,

30

- 58 -

melarsoprol, benznidazole, their metabolites, salts derivatives or any other anti-parasitic agent thereof .

5 36. The use of a pharmaceutical formulation as claimed in claims 27 to 35, wherein the composition is micronized.

37. The use of a pharmaceutical formulation as claimed in claims 27 to 36, wherein the composition enhances endogenous hsp levels.

10 38. The use of a pharmaceutical formulation as claimed in claims 27 to 37, wherein the composition enhances endogenous precursor dendritic cell levels.

39. The use of a pharmaceutical formulation as claimed in claims 27 to 38, wherein the pharmaceutical formulation has an enteric coating.

15 40. The use of a pharmaceutical formulation as claimed in claim 39, wherein the enteric coating is made of a polymer or copolymer.

20 41. The use of a pharmaceutical formulation as claimed in claim 40 wherein the polymer or copolymer is selected from the group consisting of poly(lactic-glycolic acid) polyester, cellulose acetate phthalate, hydroxypropyl-methyl cellulose phthalate poly(butyl methacrylate), (2-dimethyl aminoethyl) methacrylate, and methyl methacrylate.

25 42. The use of a pharmaceutical formulation as claimed in claims 27 to 41, wherein the pharmaceutical formulation is administered enterally, parenterally, topically, orally, rectally, nasally or vaginally.

30 43. The use of a pharmaceutical formulation as claimed in claims 27 to 42, wherein the composition is formulated into liposomes or carbohydrate vehicles.

44. The use of a pharmaceutical formulation as claimed in claim 43, wherein the liposomes or carbohydrate vehicles are targeted to HIV infected cells by putting

- 59 -

viral antibodies on its surface.

45. The use of a pharmaceutical formulation as claimed in claim 44, wherein the viral antibodies are directed to the HIV coat protein gp160 and/or gp120.

5

46. The use of a pharmaceutical formulation as claimed in claims 27 to 45, wherein the pharmaceutical formulation is administered intermittently.

47. The use of a pharmaceutical formulation as claimed in claims 27 to 46, wherein the pharmaceutical formulation is administered to a mammal.

10

48. The use of a pharmaceutical formulation as claimed in claim 47, wherein said mammal is a neonate and said administering is effected prior to delivery of said neonate and/or during delivery of said neonate.

15

49. The use of a pharmaceutical formulation as claimed in claims 27 to 48, wherein said compounds of the present invention acts as a prodrug.

50. The use of a pharmaceutical formulation for the manufacture of a medicament for sensitising a resistant neoplasia to subsequent therapy comprising administering to a patient in need thereof a therapeutically effective amount of composition as claimed in claims 1 to 6.

20

51. The use of a pharmaceutical formulation as claimed in claim 50, wherein the pharmaceutical formulation further includes at least one conventional chemotherapeutic agent.

25

52. The use of a pharmaceutical formulation as claimed in claim 51, wherein the chemotherapeutic agent is selected from the group comprising flutamide and luproside, antioestrogens, such as tamoxifen, antimetabolites and cytotoxic agents, such as daunorubicin, fluorouracil, floxuridine, interferon alpha, methotrexate, plicamycin, mecaptopurine, thioguanine, adramycin, carmustine, lomustine, cytarabine, cyclophosphamide, doxorubicin, estramustine,

30

- 60 -

altretamine, hydroxyurea, ifosfamide, procarbazine, mutamycin, busulfan, mitoxantrone, carboplatin, cisplatin, streptozocin, bleomycin, dactinomycin and idamycin, hormones such as, medroxyprogesterone, estramustine, ethinyl oestradiol, oestradiol, leuprolide, megestrol, octreotide, diethylstilbestrol, chlorotrianisene, etoposide, podophyllotoxin, and goserelin, nitrogen mustard derivatives such as, melphalan, chlorambucil, methlorethamine and thiotepa, steroids such as, betamethasone, and other antineoplastic agents such as live *Mycobacterium bovis*, dicarbazine, asparaginase, leucovorin, mitotane, vincristine, vinblastine and texotere, cyclophosphamide, adriamycin, 5-fluorouracil, hexamethylmelamine, Acivicin; Aclarubicin; Acodazole Hydrochloride; AcrQnine; Adozelesin; Aldesleukin; Altretamine; Ambomycin; Ametantrone Acetate; Aminoglutethimide; Amsacrine; Anastrozole; Anthramycin; Asparaginase; Asperlin; Azacitidine; Azetepa; Azotomycin; Batimastat; Benzodepa; Bicalutamide; Bisantrone Hydrochloride; Bisnafide Dimesylate; Bizelesin; Bleomycin Sulfate; Brequinar Sodium; Bropirimine; Busulfan; Cactinomycin; Calusterone; Caracemide; Carbetimer; Carboplatin; Carmustine; Carubicin Hydrochloride; Carzelesin; Cedefingol; Chlorambucil; Cirolemycin; Cisplatin; Cladribine; Crisnatol Mesylate; Cyclophosphamide; Cytarabine; Dacarbazine; Dactinomycin; Daunorubicin Hydrochloride; Decitabine; Dexormaplatin; Dezaguanine; Dezaguanine Mesylate; Diaziquone; Docetaxel; Doxorubicin; Doxorubicin Hydrochloride; Droloxifene; Droloxifene Citrate; Dromostanolone Propionate; Duazomycin; Edatrexate; Eflomithine Hydrochloride; Elsamitrucin; Enloplatin; Enpromate; Epiripidine; Epirubicin Hydrochloride; Erbulozole; Esorubicin Hydrochloride; Estramustine; Estramustine Phosphate Sodium; Etanidazole; Ethiodized Oil I 131; Etoposide; Etoposide Phosphate; Etoprine; Fadrozole Hydrochloride; Fazarabine; Fenretinide; Floxuridine; Fludarabine Phosphate; Fluorouracil; Flurocitabine; Fosquidone; Fostriecin Sodium; Gemcitabine; Gemcitabine Hydrochloride; Gold Au 198; Hydroxyurea; Idarubicin Hydrochloride; Ifosfamide; Ilmofofosine; Interferon Alfa-2a; Interferon Alfa-2b; Interferon Alfa-n1; Interferon Alfa-n3; Interferon Beta- I a; Interferon Gamma- I b; Iproplatin; Irinotecan Hydrochloride; Lanreotide Acetate; Letrozole; Leuprolide Acetate; Liarozole Hydrochloride; Lometrexol Sodium; Lomustine; Losoxantrone Hydrochloride; Masoprocil;

- 61 -

Maytansine; Mechlorethamine Hydrochloride; Megestrol Acetate; Melengestrol
 Acetate; Melphalan; Menogaril; Mercaptopurine; Methotrexate; Methotrexate
 Sodium; Metoprine; Meturedopa; Mitindomide; Mitocarcin; Mitocromin;
 Mitogillin; Mitomalcin; Mitomycin; Mitosper; Mitotane; Mitoxantrone
 5 Hydrochloride; Mycophenolic Acid; Nocodazole; Nogalamycin; Ormaplatin;
 Oxisuran; Paclitaxel; Pegaspargase; Peliomycin; Pentamustine; Peplomycin
 Sulfate; Perfosfamide; Pipobroman; Pipsulfan; Piroxantrone Hydrochloride;
 Plicamycin; Plomestane; Porfimer Sodium; Porfiromycin; Prednimustine;
 Procarbazine Hydrochloride; Puromycin; Puromycin Hydrochloride; Pyrazofurin;
 10 Riboprine; Rogletimide; Safmgol; Safingol Hydrochloride; Semustine;
 Simtrazene; Sparfosate Sodium; Sparsomycin; Spirogermanium Hydrochloride;
 Spiromustine; Spiroplatin; Streptonigrin; Streptozocin; Strontium Chloride Sr 89;
 Sulofenur; Talisomycin; Taxane; Taxoid; Tecogalan Sodium; Tegafur;
 Teloxantrone Hydrochloride; Temoporfin; Teniposide; Teroxirone; Testolactone;
 15 Thiamiprine; Thioguanine; Thiotepa; Tiazofurin; Tirapazamine; Topotecan
 Hydrochloride; Toremifene Citrate; Trestolone Acetate; Triciribine Phosphate;
 Trimetrexate; Trimetrexate Glucuronate; Triptorelin; Tubulozole Hydrochloride;
 Uracil Mustard; Uredopa; Vapreotide; Verteporfin; Vinblastine Sulfate;
 Vincristine Sulfate; Vindesine; Vindesine Sulfate; Vinepidine Sulfate;
 20 Vinglycinat Sulfate; Vinleurosine Sulfate; Vinorelbine Tartrate; Vinrosidine
 Sulfate; Vinzolidine Sulfate; Vorozole; Zeniplatin; Zinostatin; Zorubicin
 Hydrochloride, 20-epi-1,25 dihydroxyvitamin D3; 5-ethynyluracil; abiraterone;
 aclarubicin; acylfulvene; adecypenol; adozelesin; aldesleukin; ALL-TK
 antagonists; altretamine; ambamustine; amidox; amifostine; aminolevulinic acid;
 25 amrubicin; atrsacrine; anagrelide; anastrozole; andrographolide; angiogenesis
 inhibitors; antagonist D; antagonist G; DHEA; brominepiandrosterone;
 epiandrosterone; antarelix; anti-dorsalizing morphogenetic protein-1;
 antiandrogen, prostatic carcinoma; antiestrogen; antineoplaston; antisense
 oligonucleotides; aphidicolin glycinate; apoptosis gene modulators; apoptosis
 30 regulators; apurinic acid; ara-CDP-DL-PTBA; arginine deaminase; asulacrine;
 atamestane; atrimustine; axinastatin 1; axinastatin 2; axinastatin 3; azasetron;
 azatoxin; azatyrosine; baccatin III derivatives; balanol; batimastat; BCR/ABL
 antagonists; benzochlorins; benzoylstauosporine; beta lactam derivatives;

- 62 -

beta-alethine; betaclamycin B; betulinic acid; bFGF inhibitor; bicalutamide;
 bisantrene; bisaziridinylspermine; bisnafide; bistratene A; bizelesin; breflate;
 broprimine; budotitane; buthionine sulfoximine; calcipotriol; calphostin C;
 camptothecin derivatives; canarypox IL-2; capecitabine; carboxamide-amino-
 5 triazole; carboxyamidotriazole; CaRest M3; CARN 700; cartilage derived
 inhibitor; carzelesin; casein kinase inhibitors (ICOS); castanospermine; cecropin
 B; cetorelix; chlorins; chloroquinoxaline sulfonamide; cicaprost; cis-porphyrin;
 cladribine; clomifene analogues; clotrimazole; collismycin A; collismycin B;
 combretastatin A4; combretastatin analogue; conagenin; crambescidin 816;
 10 crisnatol; cryptophycin 8; cryptophycin A derivatives; curacin A;
 cyclopentantraquinones; cycloplatan; cypemycin; cytarabine ocfosfate;
 cytolytic factor; cytostatin; dacliximab; decitabine; dehydrodidemnin B;
 deslorelin; dexifosfamide; dexrazoxane; dexverapamil; diaziquone; didemnin B;
 didox; diethylnorspermine; dihydro-5-azacytidine; dihydrotaxol, 9-; dioxamycin;
 15 diphenyl spiromustine; docosanol; dolasetron; doxifluridine; droloxifene;
 dronabinol; duocannycin SA; ebselen; ecomustine; edelfosine; edrecolomab;
 eflornithine; elemene; emitefur; epirubicin; epristeride; estramustine analogue;
 estrogen agonists; estrogen antagonists; etanidazole; etoposide phosphate;
 exemestane; fadrozole; fazarabine; fenretinide; filgrastim; fmasteride;
 20 flavopiridol; flezelastine; fluasterone; fludarabine; fluorodaunorubicin
 hydrochloride; forfenimex; formestane; fostriecin; fotemustine; gadolinium
 texaphyrin; gallium nitrate; galocitabine; ganirelix; gelatinase inhibitors;
 gemcitabine; glutathione inhibitors; hepsulfam; Heregulin; hexamethylene
 bisacetamide; hypericin; ibandronic acid; idarubicin; idoxifene; idramantone;
 25 ilmofofosine; ilomastat; imidazoacridones; imiquimod; immunostimulant peptides;
 insulin-like growth factor-1 receptor inhibitor; interferon agonists; interferons;
 interleukins; iobenguane; iododoxorubicin; ipomeanol, 4-; irinotecan; iroplact;
 irsogladine; isobengazole; isohomohalicondrin B; itasetron; jasplakinolide;
 kahalalide F; lamellarin-N triacetate; lanreotide; leinamycin; lenograstim;
 30 lentinan sulfate; leptolstatin; letrozole; leukemia inhibiting factor; leukocyte
 alpha interferon; leuprolide+estrogen+progesterone; leuprorelin; levamisole;
 liarozole; linear polyamine analogue; lipophilic disaccharide peptide; lipophilic
 platinum compounds; lissoclinamide 7; lobaplatin; lombricine; lometrexol;

- 63 -

lonidamine; losoxantrone; lovastatin; loxoribine; lurtotecan; lutetium texaphyrin;
 lysofylline; lytic peptides; maitansine; mannostatin A; marimastat; masoprocol;
 maspin; matrilysin inhibitors; matrix metalloproteinase inhibitors; menogaril;
 merbarone; meterelin; methioninase; metoclopramide; MIF inhibitor;
 5 mifepristone; miltefosine; mirimostim; mismatched double stranded RNA;
 mitoguazone; mitolactol; mitomycin analogues; mitonafide; mitotoxin fibroblast
 growth factor-saporin; mitoxantrone; mofarotene; molgramostim; monoclonal
 antibody, human chorionic gonadotrophin; monophosphoryl lipid A
 +myobacterium cell wall sk; mopidamol; multiple drug resistance genie inhibitor;
 10 multiple tumor suppressor 1-based therapy; mustard anticancer agent;
 mycaperoxide B; mycobacterial cell wall extract; myriaporone; N-acetyldinaline;
 N-substituted benzamides; nafarelin; nagrestip; naloxone +pentazocine;
 napavin; naphterpin; nartograstim; nedaplatin; nemorubicin; neridronic acid;
 neutral endopeptidase; nilutamide; nisamycin; nitric oxide modulators; nitroxide
 15 antioxidant; nitrullyn; O6-benzylguanine; octreotide; okicenone;
 oligonucleotides; onapristone; ondansetron; ondansetron; oracin; oral cytokine
 inducer; ormaplatin; osaterone; oxaliplatin; oxaunomycin; paclitaxel analogues;
 paclitaxel derivatives; palauamine; palmitoylrhizoxin; pamidronic acid;
 panaxytriol; panomifene; parabactin; pazelliptine; pegaspargase; peldesine;
 20 pentosan polysulfate sodium; pentostatin; pentrozone; perflubron; perfosfamide;
 perillyl alcohol; phenazinomycin; phenylacetate; phosphatase inhibitors;
 picibanil; pilocarpine hydrochloride; pirarubicin; piritrexim; placetin A; placetin B;
 plasminogen activator inhibitor; platinum complex; platinum compounds;
 platinum-triamine complex; porfimer sodium; porfiromycin; propyl bis-acridone;
 25 prostaglandin J2; proteasome inhibitors; protein A-based immune modulator;
 protein kinase C inhibitor; protein kinase C inhibitors, microalgal; protein
 tyrosine phosphatase inhibitors; purine nucleoside phosphorylase inhibitors;
 purpurins; pyrazoloacridine; pyridoxylated hemoglobin polyoxyethylene
 conjugate; raf antagonists; raltitrexed; ramosetron; ras farnesyl protein
 30 transferase inhibitors; ras inhibitors; ras-GAP inhibitor; retelliptine
 demethylated; rhenium Re 186 etidronate; rhizoxin; ribozymes; RII retinamide;
 rogletimide; rohitukine; romurtide; roquinimex; rubiginone B1; ruboxyl; safingol;
 saintopin; SarCNU; sarcophytol A; sargramostim; Sdi 1 mim tics; semustine;

- 64 -

senescence derived inhibitor 1; sense oligonucleotides; signal transduction inhibitors; signal transduction modulators; single chain antigen binding protein; sizofiran; sobuzoxane; sodium borocaptate; sodium phenylacetate; solverol; somatomedin binding protein; sonermin; sparfosic acid; spicamycin D;

5 spiromustine; splenopentin; spongistatin 1; squalamine; stem cell inhibitor; stem-cell division inhibitors; stipiamide; stromelysin inhibitors; sulfmosine; superactive vasoactive intestinal peptide antagonist; suradista; suramin; swainsonine; synthetic glycosaminoglycans; tallimustine; tamoxifen methiodide; tauromustine; tazarotene; tecogalan sodium; tegafur; tellurapyrylium;

10 telomerase inhibitors; temoporfin; temozolomide; teniposide; tetrachlorodecaoxide; tetrazomine; thaliblastine; thalidomide; thiocoraline; thrombopoietin; thrombopoietin mimetic; thymalfasin; thymopoietin receptor agonist; thymotrinan; thyroid stimulating hormone; tin ethyl etiopurpurin; tirapazamine; titanocene dichloride; topotecan; topsentin; toremifene; totipotent

15 stem cell factor; translation inhibitors; tretinoin; triacetyluridine; tricinibine; trimetrexate; triptorelin; tropisetron; turosteride; tyrosine kinase inhibitors; tyrphostins; UBC inhibitors; ubenimex; urogenital sinus-derived growth inhibitory factor; urokinase receptor antagonists; vapreotide; variolin B; vector system, erythrocyte gene therapy; velaresol; venom, anti-venom, veramine;

20 verdins; verteporfin; vinorelbine; vinxaltine; vitaxin; vorozole; zanoterone; zeniplatin; zilascorb; zinostatin stimalamer, immunostimulating drugs or therapeutic agents, their metabolites, salts and derivatives thereof .

53. The use of a pharmaceutical formulation as claimed in claims 50 to 52, wherein

25 the pharmaceutical formulation is administered in combination with radiation treatment.

54. The use of a pharmaceutical formulation as claimed in claims 50 to 53, wherein the pharmaceutical formulation is administered in combination with

30 surgery.

55. The use of a pharmaceutical formulation as claimed in claims 50 to 54, wherein the neoplasia is a precancerous lesion including syndromes represented by

- 65 -

5 abnormal neoplastic and/or dysplastic, changes of tissue comprising precancerous growths in colonic, breast, renal, central nervous, gastric, or lung tissues, or conditions such as dysplastic nevus syndrome, a precursor to malignant melanoma of the skin, dysplastic nevus syndromes, polyposis syndromes, colonic polyps, precancerous lesions of the cervix (i.e., cervical dysplasia), prostatic dysplasia, bronchial dysplasia, breast, bladder and/or skin and related conditions (e.g., actinic keratosis), whether the lesions are clinically identifiable or not.

10 56. The use of a pharmaceutical formulation as claimed in claims 50 to 55, wherein the neoplasia is prostate cancer, colon cancer, small cell lung cancer, large cell lung cancer, lung adenocarcinoma, epidermoid lung cancer, melanoma (including amelanotic subtypes), renal cell carcinoma, gastric carcinoma, cancers of the central nervous system including brain tumours, neuroblastomas, gastric carcinoma, breast cancer, ovarian cancer, testicular
15 cancer, lymphoma and leukaemia, oesophageal cancer, stomach cancer, liver cancers, prostate cancer, cervical cancer, adrenal cancer, oral or mucosal cancer, bladder cancer, pancreatic cancer, lymphoma, Hodgkins disease, sarcomas. Hematopoietic cell cancers such as B cell leukaemia/lymphomas, myelomas, T-cell leukemias/lymphomas, small cell leukemias/lymphomas, null
20 cell, sezary, monocytic, myelomonocytic and Hairy cell leukemias.

57. The use of a pharmaceutical formulation as claimed in claims 50 to 56, wherein the neoplasia is in the form of a tumour comprising an epidermoid and myeloid tumour, acute or chronic, nonsmall cell, squamous or solid.

25 58. The use of a pharmaceutical formulation as claimed in claims 50 to 57, wherein the composition is micronized.

59. The use of a pharmaceutical formulation as claimed in claims 50 to 58, wherein the pharmaceutical formulation has an enteric coating.

30

60. The use of a pharmaceutical formulation as claimed in claim 59, wherein the enteric coating is made of a polymer or copolymer.

- 66 -

61. The use of a pharmaceutical formulation as claimed in claim 60, wherein the polymer or copolymer is selected from the group consisting of poly(lactic-glycolic acid) polyester, cellulose acetate phthalate, hydroxypropyl-methyl cellulose phthalate poly(butyl methacrylate), (2-dimethyl aminoethyl) methacrylate, and methyl methacrylate.
62. The use of a pharmaceutical formulation as claimed in claims 50 to 61, wherein, the pharmaceutical formulation is administered enterally, parenterally, topically, orally, sub-lingually, rectally, nasally or vaginally.
63. The use of a pharmaceutical formulation as claimed in claims 50 to 62, wherein the composition is formulated into liposomes or carbohydrate vehicles.
64. The use of a pharmaceutical formulation as claimed in claim 63, wherein the liposomes or carbohydrate vehicles are specifically targeted to tumours by covalently attaching a monoclonal antibody directed to a tumour-associated antigen.
65. The use of a pharmaceutical formulation as claimed in claims 50 to 64, wherein the pharmaceutical formulation is administered intermittently.
66. The use of a pharmaceutical formulation as claimed in claims 50 to 65, wherein the pharmaceutical formulation is a unit dose that comprises 5-500 mg of active ingredient consisting of at least one compound of the present invention.
67. The use of a pharmaceutical formulation as claimed in claims 50 to 66, wherein the pharmaceutical formulation is administered to a mammal.
68. The use of a pharmaceutical formulation as claimed in claim 67, wherein said mammal is a neonate and said administering is effected prior to delivery of said neonate and/or during delivery of said neonate.

- 67 -

69. The use of a pharmaceutical formulation as claimed in claims 50 to 68,
wherein the composition acts as a prodrug.

5

10

(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property Organization
International Bureau



(43) International Publication Date
11 July 2002 (11.07.2002)

PCT

(10) International Publication Number
WO 02/053138 A3

(51) International Patent Classification⁷: A61K 31/343,
31/015, 45/06, A61P 35/00, 37/00, 31/04, 31/12, 33/00

(21) International Application Number: PCT/IE02/00001

(22) International Filing Date: 2 January 2002 (02.01.2002)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:
S2001/0002 2 January 2001 (02.01.2001) IE

(71) Applicant and

(72) Inventor: SHANAHAN-PRENDERGAST, Elisabeth
[IE/IE]; Baybush, Straffen, County Kildare (IE).

(74) Agent: MACLACHLAN & DONALDSON; 47 Merrion
Square, Dublin 2 (IE).

(81) Designated States (*national*): AE, AG, AL, AM, AT, AU,
AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU,

CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH,
GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC,
LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW,
MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SD, SE, SG,
SI, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ,
VN, YU, ZA, ZM, ZW.

(84) Designated States (*regional*): ARIPO patent (GH, GM,
KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW),
Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM),
European patent (AT, BE, CH, CY, DE, DK, ES, FI, FR,
GB, GR, IE, IT, LU, MC, NL, PT, SE, TR), OAPI patent
(BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR,
NE, SN, TD, TG).

Published:

— with international search report

(88) Date of publication of the international search report:
19 September 2002

For two-letter codes and other abbreviations, refer to the "Guidance Notes on Codes and Abbreviations" appearing at the beginning of each regular issue of the PCT Gazette.



WO 02/053138 A3

(54) Title: TREATMENT FOR INHIBITING NEOPLASTIC LESIONS USING INCENSOLE AND/OR FURANOGERMACRENS

(57) Abstract: The invention discloses the use of incensole and/or furanogermacrene derivatives, metabolites and precursors thereof in the treatment of neoplasia, particularly resistant neoplasia and immunodysregulatory disorders. These compounds can be administered alone or in combination with conventional chemotherapeutic, anti-rival, anti-parasite agents, radiation and/or surgery.

INTERNATIONAL SEARCH REPORT

Int. l. Application No
PCT/IE 02/00001

A. CLASSIFICATION OF SUBJECT MATTER IPC 7 A61K31/343 A61K31/015 A61K45/06 A61P35/00 A61P37/00 A61P31/04 A61P31/12 A61P33/00		
According to International Patent Classification (IPC) or to both national classification and IPC		
B. FIELDS SEARCHED		
Minimum documentation searched (classification system followed by classification symbols) IPC 7 A61K		
Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched		
Electronic data base consulted during the international search (name of data base and, where practical, search terms used) EPO-Internal, WPI Data, PAJ, MEDLINE, CHEM ABS Data, SCISEARCH, CANCERLIT, BIOSIS EMBASE, NAPRALERT		
C. DOCUMENTS CONSIDERED TO BE RELEVANT		
Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X	ABDEL WAHAB S.M. ET AL.: "The essential oil of Olibanum" PLANTA MEDICA, vol. 53, no. 4, 1987, pages 382-384, XP008003381 the whole document	1-5, 27, 28, 47
X	DOLARA P ET AL: "Local anaesthetic, antibacterial and antifungal properties of sesquiterpenes from myrrh." PLANTA MEDICA, (2000 MAY) 66 (4) 356-8., XP008003376 the whole document	1-5, 27, 28, 47
-/--		
<input checked="" type="checkbox"/> Further documents are listed in the continuation of box C. <input checked="" type="checkbox"/> Patent family members are listed in annex.		
* Special categories of cited documents:		
A document defining the general state of the art which is not considered to be of particular relevance *E* earlier document but published on or after the international filing date *L* document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified) *O* document referring to an oral disclosure, use, exhibition or other means *P* document published prior to the international filing date but later than the priority date claimed *T* later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention *X* document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone *Y* document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art. *Z* document member of the same patent family		
Date of the actual completion of the international search 6 June 2002		Date of mailing of the international search report 04/07/2002
Name and mailing address of the ISA European Patent Office, P.B. 5818 Patentlaan 2 NL - 2280 HV Rijswijk Tel. (+31-70) 340-2040, Tx. 31 651 epo nl, Fax: (+31-70) 340-3016		Authorized officer Cielen, E

INTERNATIONAL SEARCH REPORT

Int'l Application No

PCT/IE 02/00001

C.(Continuation) DOCUMENTS CONSIDERED TO BE RELEVANT

Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X	<p>WO 98 42188 A (SQUIRES MERYL) 1 October 1998 (1998-10-01)</p> <p>page 7, line 31 -page 9, line 6 page 9, line 28 - line 31 page 10, line 26 -page 12, line 16 page 12, line 28 -page 13, line 2 page 14, line 9 -page 16, line 11 page 18, line 19 -page 21, line 14 page 22, line 12 - line 27 page 31, line 21 -page 32, line 15 page 76, line 27 -page 78, line 10 claims 1-6,13,25,27,28,31,33,34</p>	1-6, 27-29, 32,42, 43,47
X	<p>WO 98 00091 A (MILLENNIUM PHARM INC) 8 January 1998 (1998-01-08)</p> <p>page 3, line 17 - line 22 page 8, line 13 -page 9, line 9 page 31, line 19 - line 26 page 32, line 1 -page 34, line 3 claims 1-4,18</p>	1-5,27, 28,30, 39-43,47
X	<p>MATSUDA H ET AL: "Inhibitory effect and action mechanism of sesquiterpenes from Zedoariae Rhizoma on D-galactosamine/lipopolysaccharide-induced liver injury." BIOORGANIC AND MEDICINAL CHEMISTRY LETTERS, (1998 FEB 17) 8 (4) 339-44., XP004136908 the whole document</p>	1-3,5, 27,28,42
X	<p>PHAN, MINH GIANG ET AL: "Antimicrobial activity of sesquiterpene constituents from some Curcuma species of Vietnam" TAP CHI HOA HOC (2000), 38(1), 91-94, XP008003372 abstract examples CMPDS1,5 page 93, paragraph 1 -page 94, column 1, paragraph 1 table 2</p>	1-5,27, 28,42,47
X	<p>EP 0 804 929 A (MASSOUD AHMED MOHAMED ALI DR) 5 November 1997 (1997-11-05)</p> <p>abstract page 2, line 17 - line 46 page 3, line 39 - line 46 page 4, line 10 - line 57 claims 1-4,9</p>	1,3,5,7, 14,19, 24,27, 42,47

-/--

INTERNATIONAL SEARCH REPORT

Int'l Application No
PCT/IE 02/00001

C.(Continuation) DOCUMENTS CONSIDERED TO BE RELEVANT		
Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X	AL-HARBI M. ET AL.: "Anticarcinogenic Effect of Commiphora molmol on Solid Tumors induced by Ehrlich Carcinoma Cells in Mice" CHEMOTHERAPY, vol. 40, no. 5, 1994, pages 337-347, XP001073770 abstract page 338, column 1, paragraphs 1,4 figures 4,6 page 345, column 1, paragraph 2 -column 2, paragraph 1 page 346, column 2, paragraph 1	1,2,7
X	UBILLAS R P ET AL: "Antihyperglycemic furanosesquiterpenes from commiphora myrrha." PLANTA MEDICA, (1999 DEC) 65 (8) 778-9., XP008003375 the whole document	1-5,27, 28,42
A	BROWN D S (REPRINT) ET AL: "A SURVEY OF 6,9-EPOXYCYCLODECA'B! FURAN SESQUITERPENES" HETEROCYCLES, (01 APR 1992) VOL. 34, NO. 4, PP. 807-834. ISSN: 0385-5414., XP008003374 OHIO STATE UNIV, EVANS CHEM LABS, COLUMBUS, OH, 43210 (Reprint) page 819, paragraph 4 page 822, paragraph 2 page 824, paragraph 2 page 828, paragraph 1	1-69
A	DOSKOTCH, RAYMOND W. ET AL: "Antitumor agents. IV. Structure of tulipinolide and epitulipinolide. Cytotoxic sesquiterpenes from Liriodendron tulipifera L" J. ORG. CHEM. (1970), 35(6), 1928-36, XP001077022 abstract page 1928, column 1, paragraph 1 - paragraph 2	1-4,7, 24,27, 28,47
A	KUPCHAN, S. MORRIS ET AL: "Tumor inhibitors. LXVIII. Liatrin, a novel antileukemic sesquiterpene lactone from Liatris chapmanii" J. AMER. CHEM. SOC. (1971), 93(19), 4916-18, XP001059177 page 4916, column 2, paragraph 1 example CMPD1	1-5,7, 13,24, 27,28,47

-/--

INTERNATIONAL SEARCH REPORT

In International Application No

PCT/IE 02/00001

C.(Continuation) DOCUMENTS CONSIDERED TO BE RELEVANT

Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
A	KUPCHAN, S. MORRIS ET AL: "Tumor inhibitors. LXVII. Eupacunin, a novel antileukemic sesquiterpene lactone from <i>Eupatorium cuneifolium</i> " J. AMER. CHEM. SOC. (1971), 93(19), 4914-16, XP001059178 page 2209, column 2, paragraph 1 example CMPD1	1-5,7, 13,24, 27,28,47
A	ULUBELEN A ET AL: "OXIDATION MECHANISM OF POTENTIAL ANTITUMOR FURANOSSESQUITERPENES FROM SMYRNIUM SPECIES" STUD ORG CHEM(AMSTERDAM) (1986) 26 P. 513-528., XP008003371 FAC PHARM, UNIV ISTANBUL, ISTANBUL TURKEY abstract page 513, paragraph 1 -page 514, paragraph 2 examples CMPDS6,12,16 page 516, paragraph 3 -page 518, paragraph 1 figures SCHEME1,2	1-5,7, 24,27, 28,47
A	DATABASE NAPRALERT 'Online! 1980 GUO Y.T. ET AL.: "Studies on Constituents of Wenezhu (<i>Curcuma aromatica salise</i>)" Database accession no. 92:80776 XP002200549 abstract & GUO Y.T. ET AL.: "Studies on the constituents of Wenezhu (<i>Curcuma aromatica salise</i>)" YAO HSEUH HSUEH PAO, 1980, pages 251-252,	7,27,28
P,X	ZHU N ET AL: "Furanosesquiterpenoids of <i>Commiphora myrrha</i> ." JOURNAL OF NATURAL PRODUCTS, (2001 NOV) 64 (11) 1460-2., XP001074700 abstract page 1460, column 1, paragraph 1 page 1462, column 1, paragraph 2 --- -/--	1-5,7, 13,19,24

INTERNATIONAL SEARCH REPORT

International Application No

PCT/IE 02/00001

C.(Continuation) DOCUMENTS CONSIDERED TO BE RELEVANT

Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
------------	--	-----------------------

P,A

WO 01 45699 A (NAKSHATRI HARIKRISHNA
;SWEENEY CHRISTOPHER J (US); ADVANCED RES
AN) 28 June 2001 (2001-06-28)

1,2,5,
7-14,
17-19,
22-24,
50-62,
65-67

page 2, line 19 -page 3, line 15
page 4, line 27 -page 5, line 10
page 6, line 20 -page 7, line 4
page 7, line 21 -page 9, line 18
examples 4,5
claims 1,2,6-15,17,21,23

INTERNATIONAL SEARCH REPORT

International application No.
PCT/IE 02/00001

Box I Observations where certain claims were found uns archabl (Continuation f item 1 of first sheet)

This International Search Report has not been established in respect of certain claims under Article 17(2)(a) for the following reasons:

1. ☐ Claims Nos.:
because they relate to subject matter not required to be searched by this Authority, namely:
2. ☒ Claims Nos.:
because they relate to parts of the International Application that do not comply with the prescribed requirements to such
an extent that no meaningful International Search can be carried out, specifically:
see FURTHER INFORMATION sheet PCT/ISA/210
3. ☐ Claims Nos.:
because they are dependent claims and are not drafted in accordance with the second and third sentences of Rule 6.4(a).

Box II Observations where unity of invention is lacking (Continuation of item 2 of first sheet)

This International Searching Authority found multiple inventions in this international application, as follows:

1. ☐ As all required additional search fees were timely paid by the applicant, this International Search Report covers all
searchable claims.
2. ☐ As all searchable claims could be searched without effort justifying an additional fee, this Authority did not invite payment
of any additional fee.
3. ☐ As only some of the required additional search fees were timely paid by the applicant, this International Search Report
covers only those claims for which fees were paid, specifically claims Nos.:
4. ☐ No required additional search fees were timely paid by the applicant. Consequently, this International Search Report is
restricted to the invention first mentioned in the claims; it is covered by claims Nos.:

Remark on Protest

- ☐ The additional search fees were accompanied by the applicant's protest.
- ☐ No protest accompanied the payment of additional search fees.

FURTHER INFORMATION CONTINUED FROM PCT/ISA/ 210

Continuation of Box I.2

1. Present claims 1-69 relate to compounds which actually are not well-defined. The use of the definitions "one or more compound of the present invention", "derivatives", "metabolites", "analogues", "mimic molecules", "cembranoids", "cembranoid alcohols", "furanogermacrens", "furanosesquiterpene furanogermacrens", "a conventional chemotherapeutic agent" (claim 8), "an anti-viral agent", "an anti-parasite agent", "antiestrogens", "antimetabolites", et cetera, et cetera, "wherein the compounds act as a prodrug", in the present context is considered to lead to a lack of clarity within the meaning of Article 6 PCT.

Moreover, present claims 2, 5-69 refer to a very large number of possible compounds. Many of the compounds enumerated in claims 3 and 4 do not fall within the general Formulae (1) and (2) of claim 2.

Support within the meaning of Article 6 PCT and/or disclosure within the meaning of Article 5 PCT is to be found for only a very small proportion of the compounds claimed. In the present case, the claims so lack support, and the application so lacks disclosure, that a meaningful search over the whole of the claimed scope is impossible. Consequently, the search has been carried out for those parts of the claims which appear to be supported and disclosed, namely those parts relating to the compounds for which their pharmacological activity has been demonstrated; i.e. incensole and furanogermacren.

In principle, based on the different structures of the compounds claimed, an objection of lack of unity could be raised. For efficiency reasons, at present, however, no such objection was made. Such objection may likely be raised in substantive examination.

2. Present claims 7-12, 15-26, 27, 28, 30-49, 50-55, 58-69 relate to diseases which actually are not well-defined. The use of the definitions "a precancerous lesion", "syndromes represented by abnormal neoplastic ... or lung tissues", "bladder and/or skin and related conditions", "whether the lesions are clinically identifiable or not", "an immunodysregulatory condition", "wherein the immunodysregulatory condition is caused by ... gastrointestinal irritation or any combination of the foregoing", "enhances endogenous hsp levels", "enhances endogenous precursor dendritic levels", "sensitising a resistant neoplasia", et cetera, in the present context is considered to lead to a lack of clarity within the meaning of Article 6 PCT. The lack of clarity is such as to render a meaningful complete search impossible. Consequently, the search has been restricted to the diseases specifically mentioned in claims 12-14, 28, 29, 56 and 57 (as far as clear).

In principle, based on the different etiologies of the claimed therapeutic applications, an objection of lack of unity could be raised. For efficiency reasons, at present, however, no such objection was made. Such objection may likely be raised in substantive examination.

The applicant's attention is drawn to the fact that claims, or parts of claims, relating to inventions in respect of which no international search report has been established need not be the subject of an international preliminary examination (Rule 66.1(e) PCT). The applicant is advised that the EPO policy when acting as an International Preliminary Examining Authority is normally not to carry out a preliminary examination on matter which has not been searched. This is

FURTHER INFORMATION CONTINUED FROM PCT/ISA/ 210

the case irrespective of whether or not the claims are amended following receipt of the search report or during any Chapter II procedure.

INTERNATIONAL SEARCH REPORT

Information on patent family members

International Application No

PCT/IE 02/00001

Patent document cited in search report		Publication date	Patent family member(s)	Publication date
WO 9842188	A	01-10-1998	US 6350784 B1	26-02-2002
			AU 727339 B2	07-12-2000
			AU 6771898 A	20-10-1998
			BR 9807892 A	22-02-2000
			CN 1258191 T	28-06-2000
			EE 9900436 A	17-04-2000
			EP 0980203 A1	23-02-2000
			HU 0001379 A2	28-08-2000
			JP 2000119188 A	25-04-2000
			JP 2001527541 T	25-12-2001
			NO 994639 A	24-11-1999
			NZ 500002 A	28-09-2001
			PL 336168 A1	05-06-2000
			SK 131899 A3	11-12-2000
			TR 9902674 T2	21-02-2000
			WO 9842188 A1	01-10-1998
WO 9800091	A	08-01-1998	US 5917084 A	29-06-1999
			AU 4325897 A	21-01-1998
			WO 9800091 A2	08-01-1998
			US 6060509 A	09-05-2000
EP 0804929	A	05-11-1997	JP 10298097 A	10-11-1998
			US 6077513 A	20-06-2000
			EP 0804929 A2	05-11-1997
WO 0145699	A	28-06-2001	AU 2439201 A	03-07-2001
			WO 0145699 A1	28-06-2001